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Abstract of the Dissertation

Devising a Scalable Synthesis to Probe
the G-Protein Cell Receptor Signaling Pathway
By
Matthew Robert Medcalf
Doctor of Philosophy in Chemistry
Washington University in St. Louis, 2019
Professor Kevin D. Moeller, Chair

The G-protein coupled cell receptor signaling pathway is amongst the largest and most
diverse class of cell-surface receptors in the body. Nearly 800 different genes encode for these
cell membrane receptors which are responsible for mediating a variety of hormones,
neurotransmitters, and sensory stimuli through the activation of intracellular G proteins. To date,
roughly 34% of pharmaceuticals on the market target GPCR’s, but despite this fact, there are still
many difficulties associated with targeting this family of receptors. The vast number of GPCR’s,
disease states resulting from a dysregulation of multiple GPCR signaling pathways, and
difficulties crystalizing and purifying the receptor—G-protein complex all pose significant
challenges for targeting GPCR’s. Due to these challenges, in recent years there has been a
growing interest in targeting the intracellular G protein as an alternative to the extracellular
GPCR. For example, two known natural products YM-254890 and FR-900359, isolated from
Chromobacterium sp. QS3666 and Ardisia Crenata respectively, potently and selectively inhibit
signaling by Gq/11-class G-protein α subunits by trapping them in their inactive GDP-bound
states. As part of an effort to better understand how these natural products operate and to develop
xi

chemical probes for the Gq signaling pathway we have developed a scalable solution phase
synthesis of simplified analogs of YM/FR that retain important regions responsible for binding to
Gαq.
Through the use of this convergent synthesis with a longest linear sequence of eight steps
with an overall yield of 11.6%. We have successfully synthesized multiple analogs used to
probe the G-protein cell receptor signaling pathway. While the analogs synthesized to date are
not as potent as YM or FR, they do selectively bind to Gαq. With these results in place, we are
now probing the factors that are responsible for binding and potency of the analogs for Gq, along
with factors that determine the selectivity of the molecules for Gαq.
To this end, we have developed a new convergent synthesis, applying the lessons learned
from our second-generation synthesis, that returns functionality found in the natural products.
We believe the instillation of the “bottom bridge”, a dimer of an N-Me-O-Me-Thr and N-Ac-Thr,
will provide conformational constraint and return activity lost in the first generation of analogs.
Once more active analogs have been found, these molecules will be used as probes for
understanding the biological function of the Gq signaling pathway and as potential lead
compounds for the development of future therapeutics.

xii

Chapter One: Introduction and Background
1.1 G Protein Cell Receptor Signaling Pathway
The G-protein cell receptor (GPCR) signaling pathway is the largest membrane protein
family with nearly 800 receptors that regulate a wide variety of cellular or physiological
processes, and a wide variety of disease states. This is reflected in the sheer number of
pharmaceuticals that target the GPCR, accounting for over a third of the drugs currently
available on the market.1,2 Every day, numerous neurotransmitters, chemokines, local mediators,
and sensory stimuli exert their effects on a cell by binding to heptahelical membrane receptors
coupled to heterotrimeric G proteins.1,3,4
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D

Figure 1.1 – G Protein Cell Signaling Pathway
Image from: Rensing, D. T. (May 27, 2016). Synthesis of Simplified YM-254890 Analogs, Washington
University in St. Louis.
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In a healthy cell, the GPCR signaling cascade is represented in Figure 1.1. First, a ligand
binds to a cell surface receptor (step B), promoting exchange of guanosine diphosphate (GDP)
for guanosine triphosphate (GTP) on the Gα-subunit of the intracellular heterotrimeric G protein
(Step C). The GTP bound Gα subunit then disassociates from the Gβγ dimer (step D). These
subunits can then turn on a variety of downfield effectors. Upon completion of the cell signal,
GTP is cleaved to GDP by the GTPase domain, one of the two domains within the Gα subunit
(step E). The Gα subunit then re-associates with the Gβγ dimer, terminating the signal (step F),
thus resetting the catalytic cell cycle.
While the process of GPCR regulated signaling is well understood, much less is known
about the intracellular G proteins. The primary means by which the biochemistry community
analyzes G protein function is through genetic manipulation where changes are made to
individual amino acids within the G protein in order to examine the resulting changes in the
signaling pathway. This approach is challenging due to the complexity of GPCR/G protein pairs
and cellular adaptations to the genetic modifications, such as the rewiring of signaling
pathways.5,6 These challenges, coupled with the knowledge that roughly 10-15% of all cancers
are driven by a constitutively active mutant G protein α-subunit (step D), make alternative
strategies for gaining insight into the GPCR signaling pathways attractive. Among these
alternatives, molecules that selectively bind in a reversible manner and inhibit intracellular G
proteins can serve as invaluable probes of specific G protein signaling pathways and as potential
starting points for the development of new therapeutics. For this reason, such molecules are
important synthetic targets.7

2

1.2 Targeting Intracellular G Proteins
To date, only a handful of molecules directly target intracellular G proteins. Two such
molecules are pertussis toxin and cholera toxin that covalently bind to Gαi and Gαs respectively
and have been used to map these cell signaling pathways.8,9 In addition, the natural products
YM-254890 (YM) and FR900359 (FR) (Figure 1.2) are known to potently and selectively bind
to Gαq/11 in a pseudo-irreversible manner, trapping the α-subunit in its inactive GDP-bound
state. These two natural products and their respective analogs are the only molecules known to
behave in this manner.

Figure 1.2 – YM-254890 & FR900359
YM and FR were isolated from Chromobacterium sp. QS366 and the ornamental plant
Ardisia crenata, respectively. They are both cyclic depsipeptides comprised of seven different
amino acids, a twenty-two membered macrocycle, with eleven different stereocenters, and
multiple ester, amide, and NMe amide bonds. The core structures of YM and FR differ in only
two areas, highlighted red in Figure 1.2. FR contains a β-hydroxy leucine within the “bottom
bridge” of macrocycle (compared to a threonine within YM) and a propionate derivative on the
3

β-hydroxy leucine tail of the macrocycle (compared to an acetyl residue found in YM). These
two slight changes impart a three-fold increase in potency found in FR.11 While YM and FR are
promising lead molecules, they are not isolated in high yields from natural sources, and efforts to
synthesize these molecules in lab have primarily relied on solid state peptide chemistry. While a
combination of solution phase and solid-state peptide chemistry has allowed for the completion
of structure activity relationship (SAR) studies involving these molecules, it has not led to the
generation of either of the natural products or their respective analogs in high yield.10-14 To this
end, we propose a scalable synthesis of YM and FR analogs through a convergent route via
exclusively solution-phase synthesis. Prior to the discussion of this synthesis, we should first
focus on the knowledge available from SAR studies following isolation and synthesis of a
variety of analogs of YM and FR. All available information is important for guiding the design
and synthesis of new analogs. It is important to note that much of this information has become
available during our synthetic efforts that will be discussed in Chapter 2.

1.3 What We Know So Far
To date, fifteen different analogs of FR have been synthesized or isolated, and more than
35 different analogs of YM.14 While no analogs have been found with improved potency and
efficacy over that of the natural product FR, much has been learned about what portions of this
molecule appear to be necessary for binding. We will discuss these changes from left to right in
individual amino acids labeled in Figure 1.3.
Changes of the iso-propyl groups of β-HyLeu1 (often referred to as the β-hydroxy
leucine tail) and β-HyLeu2 are not well tolerated and result in loss of potency and efficacy in
comparison to the parent compound. However, in β-HyLeu1 multiple analogs with changes at
4

the acetyl group (R = CH3, CH2CH3, CH2SCH3) have been isolated and screened with minimal
observed change in activity.10,15

Figure 1.3 – Labeled YM & FR Structure
Changes within the N-MeAla3 and Ala4 have been shown to be tolerated. The methyl
groups of the alanine have been substituted with phenyl rings resulting in no significant loss in
activity. This information is consistent with the observation that the top bridge of the molecule is
solvent exposed and resides outside of the binding region within Gαq. This is particularly
relevant as these sites may prove suitable for future installation of cross-linking moieties to add
conformational rigidity to simplified analogs or fluorescent groups for various biological
assays.12 The N-MeDha may provide a necessary conformational constraint, as illustrated by the
subsequent loss in activity following the hydrogenation of the double bond. It is worth noting
there is a significant disparity in activity between the resulting N-MeAla and N-Me-D-Ala.
Hydrogenation leading to N-MeAla lead to a 16 fold loss in potency in comparison to the natural
product YM, where a 160 fold loss in potency is observed in the case of N-Me-D-Ala.10,15 The
difference between YM and FR, an Ac-Thr7 and Ac-β-HyLeu7, imparts three-fold more
potency to FR. Lastly, changing the N-Me amide to a typical amide bond of the N5

MeThr(OMe)8 results in a nearly 500 fold loss in potency as compared to the natural product
YM.10 With this knowledge in hand we can now discuss a scalable synthesis of YM and FR
analogs through a convergent route via solution phase synthesis.

1.4 Scaling through Simplified Analogs
The use of a Function Oriented Synthesis was made popular by Paul Wender and
coworkers in their synthesis of Bryostatin analogs, although this overall strategy has been
employed by medicinal chemists for many years.16 While this idea will not be discussed at length
here, the main concept is to retain the pharmacophore within a complex natural product, while
stripping away some of its functionality, thus shortening the overall total synthesis. This was
accomplished in the synthesis of simplified analogs of Bryostatin, shortening the synthesis of the
molecule from more than seventy steps, to less than thirty.17,18

Figure 1.4 – YM-254890 & WU-07047 Structures
This strategy was first applied to the synthesis of simplified analogs of YM by Rensing
et. al. from our group. Their approach is highlighted in Figure 1.4. The red regions represent
regions of YM that were shown to bind to Gαq in an X-ray crystal structure of YM-Gαq
6

complex.19 The asterisks represent direct points of contact within Gαq, and the numbers indicate
intramolecular hydrogen bonds meant to stabilize the binding conformation of YM to Gαq. The
intent was to simplify the groups bridging the points of contact with simplified alky chains and
alkene units that would participate in a ring closing metathesis reaction.5
While the first simplified analogs were synthesized, leading to initial screens of
biological activity, there were many challenges within the first-generation synthesis that still
needed to be addressed. Namely a problematic β-elimination involving the side chain on the lefthand side of the molecule as drawn (sometimes referred to as the β-hydroxy leucine tail). This βelimination resulted in a lowering of yields for every reaction in the synthesis following the
introduction of the side chain via esterification to acyclic molecule, inevitably making the
synthesis very difficult to repeat. With the intent of not only devising analogs that improve
efficacy, but also scaling the synthesis of those analogs for use in animal models, it became clear
that we must first address this elimination. The methods used to solve this problem, as well as
efforts to improve the potency and efficacy of analogs that target Gαq, will be discussed in the
following chapters. Greater detail about the initial approach and the issues encountered will be
included below in connection with the chemistry used to address those issues.
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Chapter 2: Synthesis of Simplified Analogs
2.1 First Generation Synthesis
Through the use of a convergent synthesis as outlined by Rensing et. al., the first
simplified analog of YM-254890 (YM) was accomplished providing analog WU-07047 (WU)
with a longest linear sequence of 10 steps and an overall yield of 6.4%. The retrosynthetic
analysis from the first-generation synthesis discussed in chapter one is outlined in Figure 2.1.

Figure 2.1 Retrosynthetic Analysis of WU-07047
With this analog in hand, WU was screened for its ability to inhibit nucleotide exchange
in Gαq and then compared with the activity associated with the natural product, YM. While this
first-generation simplified analog retained selectivity towards Gαq, it was much less potent then
the natural product and did not retain full efficacy.1 Still, the selectivity observed towards Gαq
suggests that it may serve as a great starting point for the synthesis of future analogs. For our
part, we are interested in synthesizing chemical probes for mapping the GPCR signaling
pathways. To best probe this cell signaling pathway it is of paramount importance to obtain not
only potent analogs, but analogs that retain selectivity and efficacy (evidence that the mechanism
10

of action of the simplified analog is similar to that of the natural product). With this in mind, a
second look at our first-generation synthesis suggested that reproducing this synthetic route,
varying the analogs made, and scaling the reactions to increase the amount of product isolated
would prove quite challenging. The isolation of nearly 80 mgs of WU from the initial efforts was
indeed a leap forward compared to the trace amounts (1.0 – 3.2 mgs) of material isolated through
solid-state peptide chemistry2-4, but despite literature precedent, the addition of the β-hydroxy
leucine (highlighted red in Figure 2.1) side chain in the early stages of the synthesis led to
significant losses in material along the way.

Figure 2.2 A Problematic β-Elimination
In the hands of an experienced synthetic organic chemist, it is possible to complete the
synthesis of analog WU by rapidly assembling the macrocycle. However, this sequence is
plagued with a β-elimination shown in Figure 2.2 at every step of the synthesis following
incorporation of the β-hydroxyleucine side chain prior to the formation of the macrocycle. In
order to continue to produce new analogs in a scalable fashion, it became evident we must first
turn our attention to solving the problem of this β-elimination. It was apparent that this could be
best accomplished by adding the β-hydroxy leucine sidechain last after synthesis of the intact
macrocycle.

11

2.2 Avoiding the β-Elimination
Since the natural product could be isolated without any evidence of the undesired βelimination, we believed it possible to add the β-hydroxy leucine sidechain in the final step of
our total synthesis. This idea was solidified by the experimental observation that the βelimination did not occur following formation of the macrocycle in the synthesis of the first
simplified analog WU. Interestingly, a molecular dynamics minimization of both WU and YM
using ChemBio 3D showed that in the macrocyclic products the proton responsible for this βelimination is not antiperiplanar to the ester leaving group and hence not oriented in a fashion
necessary for the elimination to readily occur (Figure 2.3). This arrangement is not observed in
the acyclic molecules where free rotation allows for the necessary antiperiplanar arrangement of
the bonds involved in the elimination reaction.

Figure 2.3 – Molecular Dynamics Minimization of YM
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In the end, molecular dynamics calculations and the experimental observations appear to
confirm our hypothesis that a strategy that places the β-hydroxyleucine side chain on last
following synthesis of the intact macrocycle could be successful. This analysis has led to the
retrosynthetic approach shown in Figure 2.4. One attractive feature of this approach is that it
does not vary our synthetic strategy significantly from the synthesis accomplished by Rensing et.
al.

Figure 2.4 – Second Generation Retrosynthetic Analysis
Upon removal of the final β-hydroxyleucine moiety in the retrosynthesis, the left-hand
portion of the macrocycle (A) is still a β-hydroxy leucine derivative that is protected with a Cterminal ester and coupled to an extended amino acid derivative. The right-hand portion (B) of
this molecule is the same coupled product of an allylglycine with a 2-hydroxy-3-phenylpropionic
acid derivative that was used in the first-generation synthesis. The macrocycle would be
constructed from a standard coupling of left- and right-hand portions of this macrocycle followed
by the same olefin metathesis strategy used previously.
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While this change may look trivial, there was no evidence in the literature of a synthetic
approach that allows for the addition of the β-hydroxyleucine side chain last. We believe this is
due to the N-Acetyl protecting group on the nitrogen of the β-hydroxyleucine side chain in the
natural product. This acetyl protecting group is not orthogonal with standard coupling
procedures. The challenges associated with this coupling will force us to either devise a new
coupling strategy, find an alternative protecting group, or exchange a protecting group in the
final steps of a total synthesis (the least appealing of the possible approaches). We began with
the assembly of the macrocycle, before addressing the challenges associated with solving this βelimination.

2.3 Right Hand Piece (RHP) Synthesis

Scheme 2.1 – RHP Synthesis
The synthesis of the right-hand portion of the molecule began with a commercially
available (S) allyl-glycine (Scheme 2.1). The availability of this starting material removed the
need to synthesize the allyl-glycine using an asymmetric Ireland Claisen rearrangement from the
first-generation synthesis. The acylation of the amine afforded compound 2.1 in 73% percent
yield. The carboxylic acid was then subjected to Mitsunobu coupling to a methyl (S)-2-hydroxy3-phenylpropionate affording coupled product in a 93% yield. It is worth noting this Mitsunobu
reaction serves two purposes. First, the reaction proceeds with stereo inversion since in the
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mechanism the hydroxyl group is first converted to a leaving group and then displaced by the
acid in an SN2-type reaction. In addition, this coupling strategy is also compatible with the
presence of the N-acetyl protecting group on the nitrogen. Under standard coupling conditions,
the activated carboxylic acid intermediate is attacked by the nucleophilic oxygen of the acetyl
group resulting primarily in oxazolone formation (Figure 2.5).

Figure 2.5 – Mitsunobu vs. Standard Coupling
Upon completion of the Mitsunobu reaction, the methyl ester was cleaved using LiI in
refluxing THF as developed by Dr. Derek Rensing. This approach not only resulted in minimal
racemization (confirmed by HNMR) but also provided a 69% yield of compound 2.3 that was
then purified via recrystallization.
With this basic strategy in place, we turned our attention to making further analogs of this
right-hand building block. To do so, we chose to protect the N-terminus of the allyl-glycine with
an ethyl carbamate in place of the N-acetyl group found in the natural product. This alternate
protection strategy would serve two purposes. First, it would improve yields relative to the
acylation reaction that led to inconsistent yields during the production of compound 2.1. Second,
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it would allow us to use an esterification reaction in place of the Mitsunobu coupling. As the
esterification reaction will not invert the stereochemistry of the alcohol like the Mitsunobu
reaction, this will provide an opportunity to probe how changes to this stereocenter might alter
the biological behavior of the natural product. What role does this stereocenter play in the
selectivity of the natural product for Gqα?

Scheme 2.2 – RHP Synthesis Continued
Following the protection of the allyl glycine derivative with ethyl chloroformate (Scheme
2.2), compound 2.4 could then be subjected to standard esterification conditions with TBTU,
resulting in an 89% yield of compound 2.5b, a product that retains the stereocenter found in the
methyl (S)-2-hydroxy-3-phenylpropionate. To obtain the stereocenter found in the natural
product we subjected compound 2.4 to Mitsunobu conditions, affording an 85% yield of
compound 2.5a. Both methyl ester substrates were then treated with LiI in THF to afford the
acid needed for the subsequent coupling reaction. It is worth noting the increase in yields, as well
as an improvement in consistency of yields, across this sequence of reactions when the ethyl
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carbamate protected amine was used in place of the acetamide. While the use of the ethyl
carbamate may require exchanging protecting groups later in the synthesis, we hoped that
analogs with the carbamate intact may retain sufficient activity as to make this additional
transformation unnecessary.
With multiple derivates of the right-hand portion now available (and a synthetic route in
place to make others), we turned our attention to the assembly of the building block containing
both the simplified top bridge and the left-hand portion of the macrocycle (Scheme 2.3).

2.4 Left Hand Piece (LHP) Synthesis

Scheme 2.3 – LHP Synthesis
The synthesis of the left-hand portion of the molecule prior to the addition of the
sidechain did not vary from the first-generation synthesis (Scheme 2.3). To this end, the Cterminus of an extended alkyl chain amino acid derivative was activated with isobutyl
chloroformate and N-methylmorpholine, and the resulting mixed anhydride treated with βhydroxy leucine in 1 M NaOH, to afford the thermodynamic amide coupling product 2-11 in
93% yield. The new C-terminus of the molecule was then converted to the allyl ester providing
the alkene necessary for the eventual ring closing metathesis. At this point we chose to leave the
free hydroxyl group in compound 2-12 unprotected, hoping this would not interfere with the
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coupling of our left- and right-hand portions of the molecule to make the precursor for the
metathesis reaction. The idea was that amide bond formation would be preferred over the
formation of an ester based on both the nucleophilicity of the amine and the stability of the
amide product. With the building blocks of our simplified analog assembled, it was time to turn
our attention to the synthesis of the macrocycle.

2.5 Macrocycle Synthesis

Scheme 2.4 – Macrocycle Synthesis
The assembly of the macrocycle (Scheme 2.4) began with the treatment of the left-hand
portion of our molecule (2-12) with standard Boc deprotection conditions using TFA. Following
the Boc deprotection, the crude product was carried forward without isolation as the
trifluoroacetate salt of the amine. The trifluoroacetate salt of compound 2-12 was treated with
HATU, DIPEA in DMF, and the previously synthesized right-hand piece of the molecule (2-6a).
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The use of these coupling conditions was chosen following a screening of the standard coupling
conditions highlighted in Table 2.1.

Table 2.1 – Macrocycle Coupling Optimization

Following purification, compound 2-15a was isolated in a 64% yield. No evidence was
obtained for an esterification product that was the result of a coupling reaction with the
unprotected alcohol in compound 2-12. This acyclic molecule was then treated with Grubbs
Generation II catalyst (Scheme 2.4) to afford compound 2-16a in 59% yield. With the
macrocycle intact, we could now turn our attention to one of two strategies to add the final βhydroxy leucine side chain.

2.6 β-Lactone Strategy
In order to couple the final β-hydroxyleucine moiety, we believed we could employ a
similar approach to the “β-Lactam Synthon Method” used by Ojima and coworkers to complete
the semi-synthesis of Taxol (Figure 2.6).2
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Figure 2.6 – β-Lactam Approach to Taxol
The use of a similar β-lactone based strategy in our case was suggested for two reasons.
First, we hoped that the use of a strained four membered ring may provide sufficient driving
force for the coupling of a challenging ester bond in a way that allowed for more gentle reaction
conditions, thus avoiding any chance of the β-elimination reaction. Second, the use of the lactone
would allow us to avoid the juggling of protecting groups necessary for a standard esterification
reaction in the presence of the alcohol in the β-hydroxyleucine sidechain (Figure 2.7).

Figure 2.7 – Coupling Strategies
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This approach leads to a shorter synthetic strategy (Path A) that would save multiple
steps relative to the more standard esterification and reduce the loss of the our most expensive
substrate. The β-hydroxyleucine costs over $1,000 for 500 mgs, the common scale of material at
the start of these protecting group sequences. Due to the significant cost of β-hydroxyleucine, we
synthesize the material “in house” as highlighted in Scheme 2-8, which we will revisit later this
chapter. Prior to this discussion, we will first focus on the synthesis of β-lactones.

Scheme 2.5 – β-Lactone Synthesis
The synthesis of this β-lactone began with the protection of the β-hydroxy leucine with
methyl chloroformate affording compound 2-7 in 89% yield (Scheme 2.5). The use of a methyl
carbamate as a protecting group was chosen in the hopes of avoiding the exchange of protecting
groups to the acetyl group found in the natural product late in the synthesis. We believed there to
be a high chance of biological tolerance due to the isolation of derivatives of the natural product
with alternative protecting groups on the β-hydroxyleucine side chain.3-7 This material was
isolated based upon its carboxylic acid and was carried forward without further purification. The
synthesis of the β-lactone was accomplished with the coupling agent TBTU and triethylamine in
DCM as outlined by Vitale et. al.8 This reaction was run at very dilute conditions in order to
avoid the bi-molecular esterification. The β-hydroxy lactone was then purified via flash column
chromatography to afford 75% yield of expected product.
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With the intent of making a variety of analogs we believed it to be possible to diversify in
the last step of our synthesis. In order to probe the tolerance of protecting groups and side chains,
a variety of β-lactones were synthesized (Table 2.2). These amino acids were chosen due to ease
of synthesis and commercial availability. Following the synthesis of our macrocycle, this diverse
array of β-lactones would allow us to rapidly make a variety of analogs via the final esterification
reaction.

Table 2.2 – β-Lactones
With these β-lactones in hand we turned out attention to devising a mock substrate
system to screen conditions for the lactone opening. We hoped to avoid having to use the
macrocycle as it was synthetically more advanced. Unfortunately, all mock substrates suffered
from the same β-elimination seen in our first-generation synthesis (Figure 2.8).
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Figure 2.8 – Substrate Screening
This elimination proved quite challenging when trying to access the success of reaction.
The screening of conditions began with previously synthesized compound 2-12. This material
was chosen as it was readily available and would most closely resemble the macrocycle.
Screening began with the use of NaHMDS, the same base used in the semi-synthesis of taxol.2
The use of an excess of a strong base, none to surprisingly, lead to exclusively β-elimination
product, though pleasingly we found evidence of successful coupling in the proton NMR when
the equivalents of base were decreased (Table 2.3). This led to the suggestion of the use of a
catalytic base system in an attempt to slow the elimination. The use of DBU:Triazole in a
catalytic fashion led to further evidence of product formation, however, rapid decomposition of
the product due to the β-elimination led to problems isolating the desired product.

Table 2.3 – Condition Screening for Lactone Opening
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This information led us to conclude that it would be necessary to test the esterification
conditions using the intact macrocycle. Following the synthesis of the macrocycle, we were able
to isolate trace amounts of the desired coupled product, but we were never able to bring obtain
satisfactory yields of the product in a reproducible fashion. It is worth noting that during the
screening of bases for the reaction, no evidence was found for the problematic β-elimination
either in proton NMR of the crude material or in the products isolated following purification of
the crude product. With no evidence of the β-elimination yet a very poor mass balance, we were
quite troubled. It appears that the low mass balance is due to a polymerization of the ring opened
β-lactone (Figure 2.9).

Figure 2.9 – Lactone Polymerization
To this end, opening of the β-lactone leads to a hydroxy anion is then capable of opening
a second lactone. Of course, that ring opening would again lead to an alkoxide capable of
opening a third lactone, and so forth and so on. Each product from the lactone opening can either
continue this chain process or undergo a separate β-elimination. We made several attempts to
control this polymerization. We began with varying the temperature of the reaction, monitoring
completion of the reaction via TLC at -78 °C, 0 °C, and RT. This led to no observable change in
yields. As we were able to recover our macrocycle starting material, we decided to use an excess
of this starting material in an attempt to slow the polymerization. This, in conjunction with
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addition of the lactone dropwise to the macrocyle over a 30-minute period did slightly improve
yields. These yields which remained unacceptable from a synthetic standpoint are highlighted in
Table 2.3. Unfortunately, it appears the β-hydroxyleucine side chain is less sterically hindered
than the macrocycle, resulting in this polymerization because the extension of the chain is more
rapid than the initial coupling reaction. As the struggles with this polymerization continued to
occur, we chose to turn our attention to standard esterification conditions to add the βhydroxyleucine side chain. This route may be longer, but if it can be consistently reproduced in
higher yields, then it would be preferable compared to that of the inconsistent β-lactone
approach. In addition to the protection strategy to be discussed below, future efforts to control
the rate of this polymerization reaction include the use of a TBS trapping group, and acid
catalysis.

2.7 β-Hydroxyleucine Protection Strategy

Scheme 2.6 – β-Hydroxy Leucine Protection Strategy
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This less elegant strategy began with the use of methyl chloroformate to protect the free
amine in our β-hydroxyleucine starting material to afford compound 2-7 in an 89% yield
(Scheme 2.6). The carboxylic acid was then protected in the presence of the free hydroxyl group
using benzyl bromide and cesium carbamate. This protecting group was chosen as opposed to the
allyl ester in the first-generation synthesis due to its ease of removal.1 The removal of the allyl
protecting group relied on the use of a Pd(0) catalyst. The yields of this deprotection were
inconsistent and depended highly on the quality of the catalyst that aged quickly. Yields could be
improved with activation of the catalyst using n-BuLi, but inconsistency was still a significant
challenge. Following the protection of the acid, the free hydroxyl group was then protected using
TBDMS triflate, affording compound 2-9 in a 98% yield. Last, the benzyl group was cleaved
using standard hydrogenation conditions. The resulting carboxylic acid was carried forward to
the next step without further purification.

Scheme 2.7 – Macrocycle Esterification
The β-hydroxyleucine side chain was added to the macrocycle using the reaction
sequence shown in Scheme 2.7. This was accomplished by treating the macrocycle (2-16a) with
EDC, catalytic DMAP, and the crude carboxylic acid (2-10) as highlighted above. A catalytic
amount of DMAP was used for the reaction in order to avoid conditions that were too basic.
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Again, we were concerned with the possibility of a β-elimination reaction following the
esterification, although there was no evidence of this elimination in either the isolated product or
the proton NMR of the crude reaction product. Following purification, the esterification reaction
afforded a 50% yield of compound 2-18a, which was then treated with TBAF to remove the
TBDMS protecting group. After deprotection, the resulting alcohol, compound 2-19a, was
isolated in a 55% yield.
In order to ensure this synthesis was as efficient as possible, we decided to determine the
necessity of purification and isolation of intermediate 2-18a. Following the esterification
reaction, the crude coupled product was then treated with TBAF. After purification, the desired
product was isolated in a 40% yield over two steps. A comparison of yields seems to indicate it
is unnecessary to isolate the coupled product prior to the subsequent TBDMS deprotection. At
this point, the methyl carbamate was left in place and was not exchanged for the N-acetyl group
found in the natural products. A topic that will be discussed in further detail in Chapter 3.

2.8 β-Hydroxyleucine Synthesis

Scheme 2.8 – β-Hydroxyleucine
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The synthesis of the syn-β-hydroxyleucine was accomplished according to literature
protocol (Scheme 2.8).9 The syn-β-hydroxyleucine was isolated in a 35% overall yield over five
steps.
This concludes the discussion regarding the synthetic efforts made to complete the
second-generation simplified analogs. We will now turn our attention to the lessons learned from
this second-generation synthesis from both a synthetic and biological standpoint in Chapter 3.
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2.10 Experimental Procedures
General Procedures:
Methyl Ester Deprotection
To a flame dried round bottom flask with stir bar was added lithium iodide (7.07 mmol) in THF
16 mL. The flask was then brought to reflux before addition of methyl ester (1.86 mmol) in THF
(15 mL). The flask was then refluxed for 24-48h. After 24-48h, the reaction was allowed to cool
to room temperature before concentrating. The resulting oil was dissolved in 50 mL chloroform
and extracted with saturated NaHCO3 (3x25 mL). The combined aqueous layers were then
brought to pH=2 and extracted with chloroform (3x30 mL). The combined organic layers were
then dried with MgSO4 and concentrated in vacuo.
Mitsunobu Esterification
Carboxylic acid (1.80 mmol), was subjected to a benzene (30 mL) azeotropic distillation to
remove any trace water. To this flask were added triphenylphosphine (1.80 mmol), followed by 4
mL THF. The flask was stirred at -30 °C before addition of alcohol (1.64 mmol) dissolved in an
additional 4 mL THF, followed by dropwise addition of 0.84 mL (1.84 mmol) of a 40 wt %
solution of diethyl azodicarboxylate in toluene. The temperature was maintained at -30 °C for 30
minutes and was then allowed to reach room temperature overnight. After 18 hours, the reaction
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was concentrated in vacuo. The resulting oil was dissolved in 50 mL EtOAc and washed with
saturated NaHCO3 (3x25 mL). The aqueous layer was then back extracted with EtOAc (2x20
mL). The combined organic layers were then dried with MgSO4 and concentrated in vacuo. The
resulting oil was purified via flash column chromatography.
Ring Closing Metathesis
To a flame dried RBF was added the acyclic diene (0.25 mmol) in DCM (160 mL). The reaction
was brought to reflux before addition of Grubbs gen. II Catalyst (0.05 mmol) in DCM (15 mL).
After 20 hours at reflux, the reaction was allowed to cool to RT before concentration in vacuo.
The resulting crude brown oil was then purified via flash column chromatography.
Macrocycle Esterification
To a flame dried RBF was added 0.1979 g (0.32 mmol) macrocycle with 0.0102 g (0.08 mmol)
DMAP and 0.0917 g (0.48 mmol) EDC. The flask was cooled to 0 °C before addition of 0.1296
g (0.40 mmol) compound 7d in DCM (2.5 mL). The reaction was then stirred and allowed to
reach RT overnight. After 48h the reaction was diluted with DCM (30 mL) and washed with
saturated NaHCO3 (3x25 mL). The aqueous layer was then back extracted with DCM (2x20
mL). The combined organic layers were then dried with MgSO4 and concentrated in vacuo. The
resulting oil was then purified via flash column chromatography.
Amide Coupling (HATU)
To a flame dried RBF was added 0.057 g (0.14 mmol) boc-protected amine, which was stirred at
room temperature in dichloromethane (3 mL) with trifluoracetic acid (1 mL). After three hours
the reaction was diluted with diethyl ether (20 mL) and concentrated in vacuo. This dilution and
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concentration were repeated three times, followed by azeotropic distillation with benzene (25
mL) in order to remove any trace water. To this flask was then added 0.0520 g (0.17 mmol)
carboxylic acid with 0.0798 g (0.21 mmol) HATU. The contents of the flask were then dissolved
in DMF (1 mL), followed by addition of 0.06 mL (0.34 mmol) DIPEA. The reaction was then
stirred at RT overnight. After 20 hours the reaction was diluted with EtOAc (30 mL) and washed
with saturated NaHCO3 (3x25 mL). The aqueous layer was then back extracted with EtOAc
(2x20 mL). The combined organic layers were then dried with MgSO4 and concentrated in
vacuo. The resulting oil was then purified via flash column chromatography.
TBDMS Deprotection
A stirring solution of 0.0135 g (0.015 mmol) TBS protected alcohol in THF (0.35 mL) was
brought to 0 °C before addition of 0.05 mL (0.045 mmol) 1 M TBAF solution in THF. After 30
minutes, the reaction was quenched with saturated ammonium chloride (15 mL). The aqueous
layer was then extracted with EtOAc (3x20 mL). The combined organic layers were then dried
with MgSO4 and concentrated in vacuo. The resulting oil was then purified via flash column
chromatography.
Lactone Formation
The β-hydroxy acid, 0.5258 g (2.13 mmol) was added to a flame dried flask with 0.8155 g (2.54
mmol) TBTU. The compounds were then dissolved in 100 mL DCM and stirred at room
temperature prior to addition of 0.92 mL triethylamine. After 20 hours the reaction was washed
with saturated NaHCO3 (3x35 mL). The aqueous layer was then back extracted with DCM (2x30
mL). The combined organic layers were then dried with MgSO4 and concentrated in vacuo. The
resulting oil was then purified via flash column chromatography.
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[Compound 2-1] A stirring solution of 0.499 g (4.33 mmol) L-allylglycine in 15 mL H2O was
brought to 0 °C. The pH was adjusted to pH=10 with 1 M NaOH. 0.46 mL (4.74 mmol) freshly
distilled Acetic Anhydride was then added dropwise to the stirring solution. The pH was readjusted to 10 and was allowed to stir and reach room temperature overnight. After 18 hours, the
reaction was brought to pH=2 with 1 M HCl. The reaction was then extracted with EtOAc (3x30
mL). The organic layer was then dried with MgSO4 and concentrated in vacuo to afford 0.5000 g
(73% yield) of compound 2-1 as a white solid. This crude product was carried forward without
any further purification.
1

H NMR (500 MHz, Chloroform-d) δ 11.50 (br, 1H), 6.32 (d, J = 7.6 Hz, 1H), 5.66 (ddt, J =

16.5, 10.4, 7.2 Hz, 1H), 5.25 – 4.95 (d, 2H), 4.73 – 4.47 (m, 1H), 2.74 – 2.37 (m, 2H), 2.02 (s,
3H); 13C NMR (126 MHz, Chloroform-d) δ 173.40, 170.27, 131.02, 118.45, 50.85, 35.03, 21.84.
Full characterization has been previously reported.1

[Compound 2-2] The reaction was set up according to General Procedure: Mistunobu
Esterification. The crude product was then purified by flash chromatography (silica gel, 100%
Et2O) to give 0.7390g (93% yield) of compound 2-2 as a white solid.
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1

H NMR (500 MHz, Chloroform-d) δ 7.36 – 7.19 (m, 5H), 5.88 (d, J = 7.9 Hz, 1H), 5.40 (ddt, J

= 17.2, 10.2, 7.2 Hz, 1H), 5.25 (dd, J = 9.5, 4.0 Hz, 1H), 5.00 – 4.95 (dd, 1H), 4.84-4.77 (m, 2H),
3.76 (s, 3H), 3.25 (dd, J = 14.3, 4.0 Hz, 1H), 3.15 – 3.08 (dd, 1H), 2.48 (m, 1H), 2.35 (m, 1H),
1.98 (s, 3H); 13C NMR (126 MHz, Chloroform-d) δ 173.72, 172.07, 172.03, 138.25, 134.40,
131.89, 131.89, 131.87, 131.26, 129.89, 121.90, 76.40, 55.19, 54.16, 39.93, 38.88, 25.76. Full
characterization has been previously reported.1

[Compound 2-3] The reaction was set up according to general procedure, Methyl Ester
Deprotection. After refluxing for 24 hours the reaction was worked up as seen in the general
procedure, Methyl Ester Deprotection. 0.2389 g (69% yield) of compound 2-3 as a yellow oil.
Recrystallization in EtOAc, followed by slow evaporation in MeOH affords pure diastereomer as
clear crystals.
1

H NMR (500 MHz, Methanol-d4) δ 7.34 – 7.19 (m, 5H), 5.61 (ddt, J = 14.1, 10.3, 7.1 Hz, 1H),

5.19 (dd, J = 9.4, 3.9, 1.9 Hz, 1H), 5.02 (dd, 1H) 4.98 - 4.91 (dd, 2H), 4.54 (td, J = 7.5, 5.3, 2.1
Hz, 1H), 3.25 (dd, J = 14.4, 3.8 Hz, 1H), 3.09 (dd, J = 14.4, 9.3, 1.9 Hz, 1H), 2.44-2.31 (m, 2H),
1.93 (s, J = 2.0 Hz, 3H); 13C NMR (126 MHz, Methanol-d4) δ 174.29, 173.72, 173.47, 138.93,
135.31, 135.26, 131.72, 130.77, 129.37, 129.26, 120.06, 76.22, 54.70, 39.50, 38.05, 23.58. Full
characterization has been previously reported.1
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[Compound 2-4] To a flame dried round bottom flask were added 0.501 g (4.36 mmol) Lallylglycine, and 0.915 g (10.9 mmol) NaHCO3. The flask was brought to 0 °C before addition
of 17.5 mL THF, followed by 11.3 mL of H2O. In two separate portions, 2.1 mL (21.8 mmol) of
Ethyl chloroformate was added over thirty minutes. The flask was allowed to stir and reach room
temperature overnight. After 20 hours, the reaction was diluted with H2O (30 mL) and then
washed with EtOAc (3x30 mL). The organic layer was then back extracted with saturated
NaHCO3 (2x25 mL). The combined aqueous layers were then acidified to pH = 2 with 1 M HCl
and extracted with EtOAc (3x30 mL). The combined organic layers were then dried with MgSO4
and concentrated in vacuo to afford 0.7313 g (90% yield) of compound 2-4 as a clear oil. This
crude product was carried forward without any further purification.
FTIR (neat) 3324, 2983, 1694, 1519, 1419, 1381, 1339, 1220, 1096, 1054 cm-1; 1H NMR (500
MHz, Chloroform-d) δ 10.73 (s, 1H), 5.74 (dq, J = 16.9, 7.9 Hz, 1H), 5.38 (d, J = 8.2 Hz, 1H),
5.16 (dd, J = 13.7, 8.6 Hz, 2H), 4.46 (q, J = 6.7 Hz, 1H), 4.15 (dq, J = 21.6, 7.3 Hz, 2H), 2.58
(dt, J = 40.4, 15.1, 6.9 Hz, 2H), 1.25 (t, J = 7.2 Hz, 3H); 13C NMR (126 MHz, Chloroform-d) δ
176.12, 156.42, 132.04, 119.47, 61.48, 53.08, 36.42, 14.47; HRMS m/z calculated for
C8H13O4N1 [M+Na]+ 210.0737, 210.0751 observed.
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[Compound 2-5a] The reaction was set up according to general procedure, Mitsunobu
Esterification. The crude product was then purified by flash chromatography (silica gel, 80%
Hexane: 20% EtOAc) to give 0.484 g (85% yield) of compound 2-5a as a white solid.
FTIR (neat) 3325, 2982, 1743, 1720, 1524, 1439, 1376, 2338, 1196, 1060 cm-1; 1H NMR (500
MHz, Chloroform-d) δ 7.30 – 7.19 (m, 5H), 5.44 (m, J = 17.1, 7.8 Hz, 1H), 5.25 (dd, J = 9.5, 4.0
Hz, 1H), 5.11 (d, J = 8.4 Hz, 1H), 4.98 (d, J = 10.2 Hz, 1H), 4.87 (d, J = 17.0 Hz, 1H), 4.51 (q, J
= 6.4 Hz, 1H), 4.10 (q, J = 7.2 Hz, 2H), 3.74 (s, 3H), 3.23 (dd, J = 14.3, 4.0 Hz, 1H), 3.09 (dd, J
= 14.3, 9.4 Hz, 1H), 2.45 (dt, J = 13.5, 6.3 Hz, 1H), 2.35 (dt, J = 13.8, 6.6 Hz, 1H), 1.24 (t, J =
7.2 Hz, 3H); 13C NMR (126 MHz, Chloroform-d) δ 171.09, 169.45, 155.73, 135.63, 131.71,
129.24, 128.58, 127.19, 119.33, 73.69, 61.14, 53.02, 52.49, 37.32, 36.53, 14.53; HRMS m/z
calculated for C18H23O6N1 [M+Na]+ 372.1418, 372.1413 observed.

[Compound 2-6a] The reaction was set up according to general procedure, Methyl Ester
Deprotection. After refluxing for 48 hours the reaction was worked up as seen in the general
procedure, Methyl Ester Deprotection. 0.3516 g (82% yield) compound 2-6a as a clear oil was
carried forward without any further purification.
FTIR (neat) 3324, 2982, 1717, 1519, 1437, 1377, 1339, 1187, 1061 cm-1; 1H NMR (500 MHz,
Methanol-d4) δ 7.33 – 7.21 (m, 5H), 5.62 (m, J = 17.2, 10.3, 7.0 Hz, 1H), 5.19 (t, J = 9.3, 3.8 Hz,
1H), 5.02 – 4.92 (m, 2H), 4.29 (t, J = 8.2, 5.1 Hz, 1H), 4.06 (t, J = 7.1, 2.6 Hz, 2H), 3.25 (dd, J =
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14.3, 3.9 Hz, 1H), 3.10 (dd, J = 14.3, 9.3 Hz, 1H), 2.46 – 2.41 (m, 1H), 2.30 (m, 1H), 1.25 (t, J =
14.1, 7.1 Hz, 3H); 13C NMR (126 MHz, Methanol-d4) δ 13C NMR (126 MHz, cd3od) δ 173.88,
173.70, 159.76, 138.93, 135.42, 131.72, 131.72, 130.73, 130.73, 129.21, 120.01, 76.22, 63.31,
56.31, 39.52, 38.27, 16.15; HRMS m/z calculated for C17H21O6N1 [M+Na]+ 358.1261, 358.1276
observed.

[Compound 2-5b] To a flame dried RBF were added 0.803 g (2.50 mmol) TBTU and 0.3784 g
(2.10 mmol) Methyl L-3-phenyllactate. This this flask was transferred 0.430 g (2.30 mmol)
compound 2-4 in 15 mL Dichloromethane. The stirring solution was brought to 0 °C before
dropwise addition of 0.91 mL (6.50 mmol) Triethylamine. The reaction was allowed to stir and
reach RT overnight. After 20 hours the reaction was diluted with DCM (50 mL). The organic
layer was then washed with saturated NaHCO3 (3x25 mL). The combined organic layer was then
dried with MgSO4 and concentrated in vacuo. The resulting oil was then then purified by flash
chromatography (silica gel, 80% Hexane: 20% EtOAc) to give 0.650 g (89% yield) of
compound 2-5b as a clear oil.
FTIR (neat) 3324, 2982, 1721, 1523, 1439, 1379, 1341, 1191, 1064; 1H NMR (500 MHz,
Chloroform-d) δ 7.32 – 7.18 (m, 5H), 5.71 (m, 1H), 5.28 (dd, J = 8.1, 4.6 Hz, 1H), 5.21 (d, J =
8.5 Hz, 1H), 5.16 – 5.06 (m, 2H), 4.44 (m, 1H), 4.09 (q, J = 7.1 Hz, 2H), 3.68 (s, 3H), 3.12 (d,
1H), 2.97 (d, J = 6.5 Hz, 1H), 2.55 (dd, J = 7.2, 6.6 Hz, 2H), 1.21 (t, J = 7.1 Hz, 3H); 13C NMR
(126 MHz, cdcl3) δ 177.18, 172.10, 158.60, 139.12, 134.79, 132.11, 131.93, 131.18, 131.17,
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131.03, 122.07, 74.00, 63.79, 54.98, 43.22, 39.87, 39.13, 17.16; HRMS m/z calculated for
C18H23O6N1 [M+Na]+ 372.1418, 372.1412 observed.

[Compound 2-6b] The reaction was set up according to general procedure, Methyl Ester
Deprotection. After refluxing for 48 hours the reaction was worked up as seen in the general
procedure, Methyl Ester Deprotection. After refluxing for 48 hours the reaction was worked up
as seen in the general procedure, Methyl Ester Deprotection. 0.2454 g (63% yield) compound 26b as a clear oil was carried forward without any further purification.
FTIR (neat) 3362, 2947, 1836, 2506, 2074, 1700, 1439, 1379, 1275, 1188, 1118, 1023; 1H NMR
(500 MHz, Methanol-d4) δ 7.34 – 7.18 (m, 5H), 5.77 (m, J = 18.5, 10.3, 7.7, 6.4 Hz, 1H), 5.23
(ddd, J = 8.1, 4.3, 1.4 Hz, 1H), 5.14 – 5.02 (m, 2H), 4.90 (s, 3H), 4.25 (dd, J = 8.7, 5.0 Hz, 1H),
4.11 – 4.03 (m, 2H), 3.32 (dq, J = 3.2, 1.6 Hz, 1H), 3.23 (dd, J = 14.4, 4.4 Hz, 1H), 3.18 – 3.08
(m, 1H), 2.58 (ddd, J = 12.1, 9.2, 5.4 Hz, 1H), 2.47 – 2.36 (m, 1H), 1.24 (tdd, J = 7.0, 5.4, 1.3
Hz, 3H); 13C NMR (126 MHz, cd3od) δ 174.04, 173.52, 159.87, 138.75, 135.78, 131.78, 130.68,
130.47, 129.21, 128.75, 119.98, 76.06, 63.33, 56.10, 39.43, 38.11, 16.16; HRMS m/z calculated
for C17H21O6N1 [M+Na]+ 358.1261, 358.1277 observed.
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[Compound 2-7] A stirred solution 0.5007 g (2.73 mmol) of the hydrochloride salt of β-hydroxy
leucine with 0.6855 g (8.16 mmol) in 9 mL H2O was brought to 0 °C. 9 mL THF was then added
to stirring solution, followed by 1.2 mL (16.3 mmol) methyl chloroformate in three 0.4 mL
portions over the next 30 minutes. Reaction was allowed to stir and reach room temperature
overnight. After 20 hours, the reaction was diluted with H2O (30 mL), and then washed with
EtOAc (2x30 mL). The organic layer was then back extracted with saturated NaHCO3 (3x25
mL). The combined aqueous layers were then acidified to pH = 2 with 1 M HCl and extracted
with EtOAc (3x30 mL). The combined organic layers were then dried with MgSO4 and
concentrated en vacuo to give 0.4974 g (86% yield) compound 2-7 as a white foaming oil that
was used without further purification.
FTIR (neat) 3338, 2946, 2835, 2477, 2071, 1703, 1404, 1120, 1027 cm-1; 1H NMR (500 MHz,
Chloroform-d) δ 6.03 (d, J = 9.6 Hz, 1H), 4.55 (d, J = 9.5 Hz, 1H), 3.85 – 3.77 (dd, 1H), 3.70 (s,
3H), 1.83 – 1.72 (m, 1H), 1.03 (d, J = 6.7 Hz, 3H), 0.93 (d, J = 7.7 Hz, 3H); 13C NMR (126
MHz, cdcl3) δ 178.47, 160.44, 80.19, 58.97, 55.31, 33.36, 21.77, 21.50; HRMS m/z calculated
for C8H15O5N1 [M+Na]+ 228.0842, 228.0852 observed.

[Compound 2-8] To a stirred solution at room temperature of 0.2873 g (1.08 mmol) compound
2-7 with 0.4352 g (1.35mmol) Cs2CO3 in 4.4 mL DMF was added 0.19 mL (1.62 mmol) benzyl
bromide drop-wise. Reaction was stirred at room temperature overnight. After 24 hours, the
reaction was diluted with 50 mL EtOAc. The organic layer was then washed with saturated
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NaHCO3 (3x30 mL). The aqueous layer was then back extracted with EtOAc (2x20 mL). The
combined organic layers were then dried with MgSO4 and concentrated in vacuo. The crude
product was then purified by flash chromatography (silica gel, 75% Hexane:25% EtOAc) to give
0.2588 g (81% yield) of compound 2-8 as a yellow oil.
FTIR (neat) 3392, 2961, 1703, 1523, 1456, 1380, 1340, 1274, 1210, 1166, 1117, 1060, 1001 cm; H NMR (500 MHz, Chloroform-d) δ 7.40 – 7.31 (m, 5H), 5.59 (d, J = 9.7 Hz, 1H), 5.20 (s,
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2H), 4.61 – 4.56 (d, 1H), 3.76 – 3.65 (m, 4H), 1.82 – 1.71 (m, 1H), 1.01 (d, J = 6.7 Hz, 3H), 0.95
(d, J = 6.7 Hz, 3H); 13C NMR (126 MHz, cdcl3) δ 174.54, 159.95, 138.04, 131.26, 131.26,
131.05, 130.76, 130.74, 80.16, 69.93, 58.94, 55.16, 33.47, 21.59, 21.53; HRMS m/z calculated
for C15H21O5N1 [M+Na]+ 318.1312, 318.1320 observed.

[Compound 2-9] To a stirring solution of 0.2402 g (0.81 mmol) compound 2-8 in 5 mL DCM
at 0 °C was added 0.47 mL (4.05 mmol) 2,6-Lutidine, followed by dropwise addition of 0.47 mL
(2.03 mmol) TBDMS-triflate. Reaction was allowed to stir and reach RT overnight. After 24
hours, the reaction was quenched with 1 M HCl (20 mL). Reaction was then extracted with DCM
(3x25 mL). The combined organic layers were then washed with 1 M KHSO4(30 mL) and brine
(30 mL). The organic layer was then dried with MgSO4 and concentrated in vacuo. The crude
product was then purified by flash chromatography (silica gel, 90% Hexane: 10% EtOAc) to
give 0.2301 g (69% yield) of compound 2-9 as a clear oil.
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FTIR (neat) 3450, 2956, 2857, 1728, 1500, 1463, 1337, 1252, 1202, 1165, 1081, 1059, 1003; 1H
NMR (500 MHz, Chloroform-d) δ 7.42 – 7.29 (m, 5H), 5.39 (d, J = 9.5 Hz, 1H), 5.16 (s, J = 1.7
Hz, 2H), 4.48 (d, J = 9.5, 1.3 Hz, 1H), 3.97 (dd, J = 6.6, 1.3 Hz, 1H), 3.70 (s, 3H), 1.89 – 1.78
(m, 1H), 1.02 – 0.88 (m, 15H), 0.03 (s, 3H), -0.08 (s, 3H); 13C NMR (126 MHz, cdcl3) δ 174.39,
159.51, 137.93, 131.26, 131.22, 130.99, 130.87, 130.85, 79.42, 69.89, 58.48, 55.00, 35.68, 28.57,
28.55, 28.31, 21.83, 20.79, -0.92, -1.63, -2.08; HRMS m/z calculated for C21H35O5N1Si1
[M+Na]+ 432.2177, 432.2177 observed.

[Compound 2-10] To a flame dried RBF containing 0.172 g (0.42 mmol) compound 2-9 was
added 0.0150 g (0.13 mmol) Pd on C. The flask was put under positive pressure of H2 and stirred
vigorously in 1.8 mL MeOH. After 6 hours, the reaction was diluted with MeOH (25 mL) and
passed through a plug column of celite. The reaction was then concentrated in vacuo to give
0.116 g (86% yield) compound 2-10 as a clear oil that was used without further purification.
FTIR (neat) 2957, 2930, 2858, 1715, 1511, 1465, 1362, 1253, 1213, 1080 cm-1; 1H NMR (500
MHz, Chloroform-d) δ 5.40 (d, J = 9.1 Hz, 1H), 4.45 (d, J = 9.1, 1.5 Hz, 1H), 4.01 (dd, J = 6.7,
1.5 Hz, 1H), 3.71 (s, 3H), 1.90 – 1.77 (m, 1H), 0.95 – 0.89 (s, 15H), 0.08 (s, 3H), 0.01 (s, 3H);
C NMR (126 MHz, cdcl3) δ 179.54, 159.61, 79.67, 58.37, 55.17, 35.40, 28.56, 28.51, 28.26,
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21.75, 20.96, 20.78, -1.69, -1.94; HRMS m/z calculated for C14H29O5N1Si1 [M+Na]+ 342.1707,
342.1706 observed.
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[Compound 2-11] A stirred solution of 0.499 g (1.93 mmol) 8-(Boc-amino)octanoic acid and
0.42 mL (3.86 mmol) of 4-methylmorpholine in 5 mL THF was brought to -10 °C. To the
stirring solution 0.25 mL isobutyl chloroformate was added and maintained at -10 °C for 30
minutes. The reaction was allowed to warm to 0 °C at which time 0.545 g (2.97 mmol) of the
hydrochloride salt of β-hydroxyluecine in 3.5 mL of 1 M NaOH was added. The reaction was
allowed to warm to room temperature overnight and stirred for 24 hours. The reaction was then
diluted with 30 mL H2O, and washed with EtOAc (2x25 mL). The combined organic layers were
then extracted with saturated NaHCO3 (3x25 mL). All aqueous layers were combined and
acidified to pH=2 with 1 M HCl and extracted with EtOAc (3x30 mL). The combined organic
layers were then dried with MgSO4 and concentrated in vacuo to give 0.696 g (88% yield) of
compound 2-11 as a tan foaming oil that was carried forward without further purification.
1

H NMR (500 MHz, Methanol-d4) δ 4.69 (d, J = 2.5 Hz, 1H), 3.72 (dd, J = 9.1, 2.4 Hz, 1H), 3.03

(t, J = 7.0 Hz, 3H), 2.35 – 2.28 (m, 2H), 1.72 – 1.61 (m, 3H), 1.44 (s, 11H), 1.36 (q, J = 6.7, 5.7
Hz, 6H), 1.03 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.7 Hz, 3H); 13C NMR (126 MHz, cd3od) δ
177.70, 175.84, 159.79, 81.03, 79.36, 57.21, 42.63, 38.20, 36.20, 33.76, 32.17, 31.43, 31.35,
30.12, 29.02, 28.11, 27.28, 20.92, 20.70. Full characterization has been previously reported.1
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[Compound 2-12] To a stirring solution of 0.662 g (1.71 mmol) compound 2-11 with 0.661 g
NaHCO3 (7.87 mmol) in 10 mL DMF was added 1.3 mL (15.8 mmol) Allyl Bromide in a
dropwise fashion. The reaction was allowed to stir at room temperature overnight. After 20 hours
the reaction was diluted with 30 mL H2O, and extracted with EtOAc (3x30 mL). The combined
organic layers were then washed with brine (1x20 mL). The organic layer was then dried with
MgSO4 and concentrated in vacuo. The crude product was then purified by flash chromatography
(silica gel, 50% Hexane: 50% EtOAc) to give 0.4379 g (60% yield) of compound 2-12 as a clear
oil.
1

H NMR (300 MHz, CDCl3) δ 6.75 (d, J=9.4 Hz, 1H), 5.78 (m, J=17.2, 10.4, 5.7 Hz, 1H), 5.20 -

5.11 (m, 2H), 4.69 (d, J=9.1, 2.1 Hz, 1H), 4.51 (d, J=5.3 Hz, 2H), 3.61 (dd, J=9.4, 1.8 Hz, 1H),
2.96 (dd, J=5.9 Hz, 2H), 2.14 (t, J=7.3 Hz, 2H), 1.42 - 1.70 (m, 4H), 1.31 (s, 11H), 1.20 (br, 6H),
0.89 (d, J=7.0 Hz, 3H), 0.79 (d, J=7.0 Hz, 3H); 13C NMR (126 MHz, cdcl3) δ 176.20, 174.15,
158.72, 134.31, 121.25, 81.39, 80.04, 68.67, 56.97, 43.14, 39.02, 34.01, 33.75, 32.50, 31.45,
31.15, 31.07, 30.63, 29.18, 28.09, 21.74, 21.56. Full characterization has been previously
reported.1

[Compound 2-13] The reaction was set up according to General Procedure: Amide Coupling
(HATU). The crude product was then purified by flash chromatography (silica gel, 10% Hexane:
90% EtOAc) to give 0.0631 g (77% yield) of compound 2-13 as a yellow oil.
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FTIR (neat) 3296, 3079, 2931, 2858, 1748, 1650, 1544, 1439, 1374, 1177, 1061 cm-1; 1H NMR
(500 MHz, Chloroform-d) δ 7.24 – 7.11 (m, 5H), 6.90 – 6.79 (m, 1H), 5.90 – 5.80 (m, 2H), 5.38
– 5.30 (m, 2H), 5.30 – 5.15 (m, 2H), 5.00 – 4.88 (m, 3H), 4.58 (t, J = 11.3, 5.7, 2.7, 1.4 Hz, 2H),
4.36 (ddd, J = 7.1, 6.1, 0.9 Hz, 1H), 4.28 (dd, J = 7.0, 1.1 Hz, 1H), 4.18 (dq, J = 7.7, 6.3, 5.4 Hz,
1H), 3.32 (dd, J = 14.5, 3.6 Hz, 1H), 3.19 – 3.12 (m, 2H), 2.96 (ddd, J = 14.9, 9.6, 5.5 Hz, 1H),
2.29 – 2.10 (m, 4H), 1.95 – 1.89 (m, 4H), 1.78 (dq, J = 13.3, 6.7 Hz, 1H), 1.57 (q, J = 7.5 Hz,
2H), 1.45 – 1.33 (m, 2H), 1.31 – 1.12 (m, 5H), 0.96 (dd, J = 6.6, 0.9 Hz, 1H), 0.90 – 0.83 (m,
6H);
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C NMR (126 MHz, cdcl3) δ 176.24, 174.01, 173.43, 173.22, 171.24, 139.24, 134.30,

132.07, 132.02, 131.17, 130.99, 129.69, 122.22, 121.37, 89.59, 77.70, 73.44, 68.64, 55.38, 42.12,
41.27, 40.44, 39.08, 37.55, 34.91, 33.84, 31.77, 31.53, 30.78, 29.22, 28.58, 25.30, 19.85. HRMS
m/z calculated for C33H49O8N3 [M+Na]+ 638.3412, 638.3385 observed.

[Compound 2-14] The reaction was set up according to general procedure: Ring Closing
Metathesis. The crude product was then purified by flash chromatography (silica gel, 10%
Hexane: 90% EtOAc) to give 0.0519 g (57% yield) of compound 2-14 as a clear foaming oil.
FTIR (neat) 3294, 2931, 2858, 1746, 1653, 1542, 1439, 1375, 1176, 1061 cm-1; 1H NMR (500
MHz, Chloroform-d) δ 7.32 – 7.20 (m, 7H), 6.72 (t, J = 5.6 Hz, 1H), 6.15 (d, J = 6.3 Hz, 1H),
5.54 – 5.49 (m, 2H), 5.37 (dd, J = 9.3, 3.8 Hz, 1H), 4.64 (dd, J = 13.1, 3.6 Hz, 1H), 4.49 – 4.42
(m, 2H), 4.41 – 4.35 (m, 1H), 4.34 – 4.28 (m, 1H), 3.43 – 3.34 (m, 2H), 3.23 (ddd, J = 13.3, 8.7,
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3.7 Hz, 1H), 3.07 (dd, J = 14.4, 9.3 Hz, 1H), 2.27 (t, J = 7.5 Hz, 3H), 2.17 – 2.09 (m, 1H), 2.00
(s, 3H), 1.85 (dt, J = 13.3, 6.7 Hz, 1H), 1.70 – 1.50 (m, 4H), 1.39 – 1.20 (m, 4H), 0.94 (dd, J =
14.7, 6.8 Hz, 6H); 13C NMR (126 MHz, cdcl3) δ 178.30, 175.42, 174.97, 174.03, 172.89, 140.38,
133.18, 133.13, 132.20, 132.17, 131.95, 130.41, 130.07, 81.45, 64.73, 60.45, 57.22, 56.26, 42.60,
41.37, 39.02, 38.19, 34.44, 33.19, 29.23, 26.70, 22.93, 22.53, 22.33, 21.87, 18.16.HRMS m/z
calculated for C31H45O8N3 [M+Na]+ 610.3099, 610.3068 observed.

[Compound 2-15a] The reaction was set up according General Procedure: Amide Coupling
(HATU). The crude product was then purified via flash chromatography (silica gel, 50%
Hexane: 50% EtOAc) to give 0.197 g (64% yield) of compound 2-15a as a clear oil.
FTIR (neat) 3306, 2931, 2858, 1747, 1699, 1650, 1536, 1440, 1372, 1259, 1156, 1156, 1058 cm; H NMR (500 MHz, Chloroform-d) δ 7.31 – 7.16 (m, 5H), 6.87 – 6.79 (m, 1H), 6.55 (d, J =
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9.3 Hz, 1H), 5.89 (ddt, J = 17.2, 10.4, 5.7 Hz, 1H), 5.36 – 5.21 (m, 3H), 5.01 (dd, J = 16.8, 6.5,
3.2, 1.6 Hz, 2H), 4.84 (dd, J = 9.2, 2.2 Hz, 1H), 4.67 – 4.60 (m, 2H), 4.17 – 4.02 (m, 3H), 3.73
(dd, J = 9.0, 2.2 Hz, 1H), 3.35 (dd, J = 14.4, 3.6 Hz, 1H), 3.27 – 3.13 (m, 2H), 3.06 – 2.99 (m,
1H), 2.29 – 2.21 (m, 5H), 1.73 – 1.60 (m, 4H), 1.51 – 1.41 (m, 3H), 1.35 – 1.28 (m, 2H), 1.27 –
1.20 (m, 3H), 1.02 (d, J = 6.7 Hz, 3H), 0.96 – 0.92 (d, 3H); 13C NMR (126 MHz, cdcl3) δ 176.21,
174.17, 173.15, 171.41, 139.04, 134.35, 134.24, 132.06, 132.03, 131.00, 129.84, 129.49, 122.18,
121.20, 77.72, 73.41, 68.61, 64.17, 57.04, 56.40, 41.99, 41.26, 40.44, 39.04, 37.82, 33.81, 31.43,
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31.23, 28.96, 27.99, 21.61, 19.83, 17.12; HRMS m/z calculated for C34H51O9N3 [M+Na]+
668.3518, 668.3484 observed.

[Compound 2-16a] The reaction was set up according to general procedure: Ring Closing
Metathesis. The crude product was then purified via flash chromatography (silica gel, 40%
Hexane: 60% EtOAc) to give 0.108 g (59% yield) of compound 2-16a as a tan oil.
FTIR (neat) 3305, 2931, 1700, 1652, 1537, 1454, 1372, 1260, 1175, 1059 cm-1; 1H NMR (500
MHz, Chloroform-d) δ 7.32 – 7.19 (m, 5H), 6.67 (d, J = 5.7 Hz, 1H), 6.47 (dd, J = 13.1, 8.9 Hz,
1H), 5.75 (d, J = 7.2 Hz, 1H), 5.56 (ddd, J = 16.9, 8.2, 6.2 Hz, 1H), 5.25 (dd, J = 9.3, 3.7 Hz,
1H), 5.15 (dt, J = 15.5, 5.0 Hz, 1H), 4.74 (dd, J = 8.7, 2.0 Hz, 1H), 4.62 (dd, J = 13.3, 5.1 Hz,
1H), 4.38 – 4.29 (m, 1H), 4.11 (dq, J = 11.4, 7.1 Hz, 2H), 3.74 (ddd, J = 8.9, 4.9, 1.9 Hz, 1H),
3.48 – 3.37 (m, 1H), 3.32 (dt, J = 14.5, 4.7 Hz, 1H), 3.19 – 3.03 (m, 2H), 2.87 (t, J = 5.1 Hz,
1H), 2.39 – 2.22 (m, 3H), 2.14 (dt, J = 14.2, 7.2 Hz, 0H), 1.78 – 1.69 (m, 1H), 1.68 – 1.60 (m,
1H), 1.40 – 1.19 (m, 4H), 1.02 (dd, J = 16.3, 6.6 Hz, 3H), 0.97 – 0.90 (m, 3H); 13C NMR (126
MHz, cdcl3) δ 176.77, 174.04, 173.32, 171.68, 159.20, 139.13, 131.03, 130.54, 130.26, 129.62,
129.54, 129.44, 78.22, 66.68, 64.04, 63.07, 57.07, 56.57, 41.75, 40.31, 38.63, 36.84, 33.72,
30.78, 30.45, 27.74, 26.60, 21.56, 19.82, 17.21, 16.86; HRMS m/z calculated for C32H47O9N3
[M+Na]+ 640.3205, 640.3181 observed.
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[Compound 2-15b] The reaction was set up according General Procedure: Amide Coupling
(HATU). The crude product was then purified via flash chromatography (silica gel, 50%
Hexane: 50% EtOAc) to give 0.164 g (68% yield) of compound 2-15b as a clear oil.
FTIR (neat) 3311, 2930, 2857, 1745, 1651, 1537, 1455, 1372, 1202, 1059 cm-1; 1H NMR (500
MHz, Chloroform-d) δ 7.31 – 7.16 (m, 5H), 6.81 (d, J = 6.8 Hz, 1H), 6.53 (d, J = 9.2 Hz, 1H),
5.95 – 5.85 (m, 1H), 5.40 (td, J = 10.3, 9.1, 5.2 Hz, 2H), 5.35 – 5.09 (m, 5H), 4.85 (dd, J = 9.2,
2.1 Hz, 1H), 4.69 – 4.61 (m, 2H), 4.29 – 4.21 (m, 1H), 4.14 – 4.02 (m, 3H), 3.74 (d, J = 9.0 Hz,
1H), 3.28 (dd, J = 14.4, 4.1 Hz, 1H), 3.17 (dp, J = 19.3, 6.7 Hz, 2H), 3.07 (q, J = 7.0, 6.5 Hz,
1H), 2.44 (t, J = 6.6 Hz, 2H), 2.26 (t, J = 7.6 Hz, 2H), 1.67 (dp, J = 30.0, 7.5, 7.0 Hz, 3H), 1.43
(dt, J = 14.6, 8.5 Hz, 2H), 1.31 (qd, J = 8.9, 6.0, 5.0 Hz, 4H), 1.26 – 1.18 (m, 4H), 1.03 (d, J =
6.6 Hz, 3H), 0.94 (d, J = 6.7 Hz, 3H); 13C NMR (126 MHz, cdcl3) δ 176.21, 174.17, 173.15,
171.41, 159.27, 139.04, 134.28, 132.08, 132.03, 131.97, 131.23, 131.00, 129.49, 122.18, 121.20,
77.72, 73.41, 68.61, 64.17, 57.04, 56.40, 41.99, 41.26, 40.44, 39.04, 37.82, 33.81, 31.43, 31.23,
28.96, 27.99, 21.61, 19.83, 17.12; HRMS m/z calculated for C34H51O9N3 [M+Na]+ 668.3518,
668.3470 observed.
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[Compound 2-16b] The reaction was set up according to general procedure: Ring Closing
Metathesis. The crude product was then purified via flash chromatography (silica gel, 40%
Hexane: 60% EtOAc) to give 0.092 g (58% yield) of compound 2-16b as a tan oil.
FTIR (neat) 3307, 2929, 2856, 1720, 1655, 1532, 1455, 1373, 1259, 1176, 1059 cm-1; 1H NMR
(500 MHz, Chloroform-d) δ 7.35 – 7.21 (m, 7H), 7.21 – 7.17 (m, 3H), 6.27 (d, J = 9.0 Hz, 1H),
5.75 – 5.66 (m, 1H), 5.59 (dt, J = 15.6, 5.5 Hz, 1H), 5.42 – 5.31 (m, 2H), 4.74 (dt, J = 8.4, 3.2
Hz, 1H), 4.70 – 4.65 (m, 1H), 4.57 – 4.49 (m, 1H), 4.40 – 4.31 (m, 1H), 4.12 (dtdd, J = 10.6, 7.7,
5.5, 3.0 Hz, 3H), 3.79 (dd, J = 9.0, 2.0 Hz, 1H), 3.30 – 3.14 (m, 6H), 2.32 (dq, J = 16.5, 9.9, 8.1
Hz, 2H), 2.19 (ddd, J = 14.3, 8.3, 6.0 Hz, 1H), 1.72 (h, J = 6.6 Hz, 7H), 1.57 (dd, J = 14.4, 7.3
Hz, 1H), 1.41 (dq, J = 18.6, 6.4, 5.6 Hz, 1H), 1.35 – 1.21 (m, 25H), 1.04 (d, J = 6.5, 4.7 Hz, 3H),
0.99 – 0.93 (d, 3H); 13C NMR (126 MHz, cdcl3) δ 173.65, 171.45, 170.23, 168.41, 158.00,
135.55, 129.88, 129.67, 128.46, 128.40, 128.01, 126.96, 126.93, 75.61, 64.70, 61.46, 54.52,
54.50, 53.53, 39.07, 38.62, 37.63, 36.26, 34.94, 31.21, 30.98, 28.47, 26.15, 25.03, 19.19, 18.86,
14.54; HRMS m/z calculated for C32H47O9N3 [M+Na]+ 640.3205, 640.3157 observed.
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[Compound 2-17] The reaction was set up according to general procedure: Macrocycle
Esterification. In an effort to confirm the necessity of purification prior to subsequent TBDMS
deprotection crude material was carried forward. The crude material was then subjected to
general procedure: TBDMS Deprotection. The crude product was then purified via flash
chromatography (silica gel, 100% EtOAc) to give 8 mg (24% yield) of compound 2-17 as a tan
oil over two steps.
FTIR (neat) 3306, 2924, 2854, 1745, 1652, 1536, 1456, 1375, 1264, 1172, 1060 cm-1; 1H NMR
(500 MHz, Chloroform-d) δ 7.38 – 7.24 (m, 8H), 7.19 (d, J = 11.8 Hz, 1H), 6.77 (dd, J = 13.0,
6.1 Hz, 1H), 6.38 (q, J = 9.1, 8.2 Hz, 1H), 5.63 – 5.55 (m, 1H), 5.36 – 5.26 (m, 2H), 5.00 (dddd,
J = 28.4, 13.7, 10.6, 6.0 Hz, 2H), 4.75 – 4.67 (m, 2H), 4.60 (d, J = 15.3 Hz, 1H), 4.49 (dq, J =
12.8, 5.8, 3.5 Hz, 2H), 4.36 (d, J = 12.8 Hz, 1H), 4.25 – 4.12 (m, 2H), 3.74 (tt, J = 9.2, 4.7 Hz,
5H), 3.53 – 3.37 (m, 2H), 3.22 (ddt, J = 14.4, 9.5, 4.3 Hz, 2H), 3.07 (tdd, J = 14.1, 10.4, 4.7 Hz,
1H), 2.41 – 2.26 (m, 4H), 2.11 – 1.95 (m, 7H), 1.90 – 1.71 (m, 5H), 1.47 – 1.20 (m, 14H), 1.17 –
1.10 (m, 3H), 1.08 – 0.85 (m, 10H). 13C NMR (126 MHz, cdcl3) δ 177.81, 174.66, 174.00,
173.07, 173.05, 172.11, 159.63, 139.75, 132.25, 132.17, 131.09, 131.07, 129.53, 128.36, 128.34,
78.95, 67.40, 59.60, 59.57, 55.28, 55.23, 54.61, 41.67, 40.51, 37.98, 37.24, 33.60, 32.37, 32.34,
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30.88, 30.86, 29.61, 29.45, 26.69, 25.30, 22.11, 21.63, 21.43, 21.02. HRMS m/z calculated for
C39H58O12N4 [M+Na]+ 775.4124,775.4089 observed.

[Compound 2-18a] The reaction was set up according to general procedure: Macrocycle
Esterification. The crude product was then purified via flash chromatography (silica gel, 60%
Hexane: 40% EtOAc) to give 0.0555 g (50% yield) of compound 2-18a as a clear foaming oil.
Efforts were not made to fully characterize intermediate 2-18a as it was deemed unnecessary to
purify material prior to subsequent TBDMS deprotection.

[Compound 2-19a] The reaction was set up according to general procedure: TBDMS
Deprotection. The crude product was then purified via flash chromatography (silica gel, 70%
Hexane: 30% EtOAc) to give 0.0113 g (58% yield) of compound 2-19a as a tan oil.
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FTIR (neat) 3308, 2930, 1703, 1652, 1529, 1455, 1372, 1260, 1169, 1114, 1058 cm-1; 1H NMR
(500 MHz, Chloroform-d) δ 7.33 – 7.20 (m, 10H), 6.85 – 6.79 (m, 1H), 6.28 (d, J = 8.4 Hz, 1H),
6.02 (d, J = 7.1 Hz, 1H), 5.56 (d, J = 8.8 Hz, 2H), 5.49 – 5.41 (m, 0H), 5.39 – 5.34 (m, 1H), 5.10
(dd, J = 10.1, 3.3 Hz, 1H), 5.04 – 5.00 (m, 2H), 4.81 (dd, J = 12.0, 7.4 Hz, 1H), 4.73 (d, J = 8.5
Hz, 1H), 4.52 (dd, J = 13.9, 4.7 Hz, 1H), 4.44 (ddd, J = 9.7, 5.1, 1.7 Hz, 1H), 4.38 (q, J = 6.1 Hz,
1H), 4.22 (d, J = 13.3 Hz, 1H), 4.16 – 4.04 (m, 4H), 3.74 – 3.67 (m, 6H), 3.24 (dd, J = 14.3, 3.3
Hz, 1H), 3.18 – 3.06 (m, 1H), 2.38 – 2.21 (m, 4H), 2.12 (td, J = 9.0, 8.4, 4.7 Hz, 1H), 1.94 (ddt, J
= 21.4, 8.2, 6.7 Hz, 1H), 1.80 (ddd, J = 13.3, 8.6, 6.5 Hz, 1H), 1.75 – 1.67 (m, 1H), 1.65 – 1.56
(m, 1H), 1.53 – 1.43 (m, 1H), 1.41 – 1.31 (m, 6H), 1.29 – 1.20 (m, 7H), 1.12 – 1.04 (m, 4H),
1.04 – 0.87 (m, 14H); 13C NMR (126 MHz, cdcl3) δ 177.34, 174.52, 174.05, 173.11, 171.91,
159.64, 159.06, 139.47, 132.26, 132.21, 132.05, 131.04, 130.94, 129.48, 129.16, 80.51, 78.37,
67.55, 63.80, 63.03, 59.53, 56.29, 55.34, 41.69, 40.45, 38.13, 37.28, 33.53, 32.27, 30.66, 29.95,
27.10, 25.82, 23.69, 22.02, 21.62, 20.95, 17.24, 16.85, 16.05; HRMS m/z calculated for
C40H60O13N4 [M+Na]+ 827.4049, 827.3993 observed.

[Compound 2-18b] The reaction was set up according to general procedure: Macrocycle
Esterification. The crude product was then purified via flash chromatography (silica gel, 70%
Hexane: 30% EtOAc) to give 0.0555 g (63% yield) of compound 2-18a as a clear foaming oil.
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Efforts were not made to fully characterize intermediate 2-18b as it was deemed unnecessary to
purify material prior to subsequent TBDMS deprotection.

[Compound 2-19b] The reaction was set up according to general procedure: TBDMS
Deprotection. The crude product was then purified via flash chromatography (silica gel, 70%
Hexane: 30% EtOAc) to give 11 mg (64% yield) of compound 2-19a as a tan oil.
FTIR (neat) 3324, 2933, 1725, 1658, 1534, 1455, 1372, 1265, 1175, 1115, 1060 cm-1; 1H NMR
(500 MHz, Chloroform-d) δ 7.32 – 7.14 (m, 6H), 6.27 (d, J = 9.4 Hz, 2H), 6.18 (s, 1H), 5.60 (dp,
J = 27.5, 7.3, 6.4 Hz, 2H), 5.46 – 5.37 (m, 1H), 5.29 (d, J = 7.5 Hz, 1H), 5.06 (ddd, J = 11.2, 9.2,
1.9 Hz, 1H), 4.92 – 4.77 (m, 1H), 4.75 – 4.65 (m, 1H), 4.46 – 4.37 (m, 2H), 4.34 – 4.28 (m, 2H),
4.12 (dq, J = 10.5, 7.1 Hz, 4H), 3.75 – 3.63 (m, 5H), 3.62 (d, J = 8.8 Hz, 1H), 3.28 – 3.17 (m,
4H), 3.16 (dt, J = 14.4, 4.3 Hz, 3H), 2.55 (d, J = 14.7 Hz, 2H), 2.43 (q, J = 7.1 Hz, 1H), 2.32 (s,
2H), 2.20 (ddd, J = 14.5, 8.5, 6.0 Hz, 1H), 2.05 (s, 2H), 1.95 (dp, J = 9.2, 6.7 Hz, 1H), 1.75 (s,
7H), 1.58 – 1.51 (m, 1H), 1.42 (dd, J = 13.7, 7.0 Hz, 2H), 1.27 (ddd, J = 9.3, 6.1, 2.5 Hz, 13H),
1.11 – 0.96 (m, 8H), 0.93 (q, J = 6.0, 5.5 Hz, 10H); 13C NMR (126 MHz, cdcl3) δ 176.67,
174.26, 174.01, 172.77, 171.06, 159.79, 159.02, 138.31, 132.32, 132.29, 131.34, 131.32, 131.00,
130.29, 129.56, 81.19, 78.03, 68.27, 64.11, 63.05, 59.33, 55.54, 55.18, 41.81, 40.33, 38.65,
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37.45, 33.31, 32.19, 31.04, 30.88, 28.73, 27.47, 23.70, 21.58, 20.98, 18.06, 17.18, 16.99, 16.85;
HRMS m/z calculated for C40H60O13N4 [M+Na]+ 827.4049, 827.4000 observed.

[Compound 2-20] A stirred solution 0.5024 g (2.74 mmol) of the hydrochloride salt of βhydroxy leucine with 0.6880 g (8.16 mmol) NaHCO3 in 10 mL H2O and 10 mL THF was
brought to 0 °C. To this stirring solution was added 2.4 mL (17.2 mmol) 2,2,2trichloroethoxycarbonyl chloride in three 0.8 mL portions over the next 30 minutes. Reaction
was allowed to stir and reach room temperature overnight. After 24 hours, the reaction was
diluted with H2O (30 mL), and then washed with EtOAc (2x30 mL). The organic layer was then
back extracted with saturated NaHCO3 (3x25 mL). The combined aqueous layers were then
acidified to pH = 2 with 1 M HCl and extracted with EtOAc (3x30 mL). The combined organic
layers were then dried with MgSO4 and concentrated in vacuo to give 0.6955 g (79% yield)
compound 2-20 as a yellow foaming oil that was used without further purification.
1

H NMR (500 MHz, Chloroform-d) δ 6.22 (d, J = 9.5 Hz, 1H), 4.83 (d, J = 12.0 Hz, 1H), 4.69

(d, J = 12.0 Hz, 1H), 4.59 (dd, J = 9.6, 1.9 Hz, 1H), 3.85 (dd, J = 9.4, 1.9 Hz, 1H), 1.79 (m, J =
9.4, 6.6 Hz, 1H), 1.05 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, cdcl3) δ
178.06, 157.95, 97.98, 80.19, 77.42, 59.08, 33.46, 21.82, 21.43; Full characterization has been
previously reported.1
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[Compound 2-21] The reaction was set up according to General Procedure: Lactone
Formation. The crude product was then purified by flash chromatography (silica gel, 80%
Hexane: 20% EtOAc) to give 0.4222 g (71% yield) of compound 2-21 as a white solid.
1

H NMR (500 MHz, Chloroform-d) δ 5.91 (d, J = 9.3 Hz, 1H), 5.53 (d, J = 8.2, 6.0, 2.1 Hz, 1H),

4.99 – 4.91 (d, 1H), 4.88 – 4.81 (d, 1H), 4.34 – 4.25 (dd, 1H), 1.93 (m, 1H), 1.15 – 1.04 (d, 3H),
0.96 (d, J = 30.4, 6.8, 2.1 Hz, 3H). 13C NMR (126 MHz, cdcl3) δ 171.17, 156.45, 85.17, 77.65,
77.49, 62.26, 31.41, 21.11, 19.91. Full characterization of compound 2-21 was not obtained as
this pathway was deemed unsuitable for future use.

[Compound 2-22] In a flame dried flask was added 0.222 g (0.73 mmol) compound 2-21 which
was then dissolved in 9.0 mL (94.9 mmol) acetic anhydride. This solution was then added via
syringe to a flask charged with 0.8560 g (13.1 mmol) freshly activated Zinc. To this flask was
added 0.18 mL (1.31 mmol) triethylamine. This reaction mixture was sonicated at 0°C for four
hours after which the reaction contents were diluted with methanol (50 mL) and filtered to
remove solid. The filtrate was then concentrated in vacuo. The crude product was then purified
by flash chromatography (silica gel, 80% Hexane: 20% EtOAc) to give 0.0359 g (29% yield) of
compound 2-22 as a pale yellow oil.
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1

H NMR (300 MHz, Chloroform-d) δ 6.29 (d, J = 8.8 Hz, 1H), 5.71 (d, J = 8.8, 5.9 Hz, 1H), 4.26

(dd, J = 10.3, 5.9 Hz, 1H), 2.07 (s, 3H), 1.94 – 1.81 (m, 1H), 1.08 (d, J = 6.5 Hz, 3H), 0.88 (d,
3H). Full characterization of compound 2-22 was not obtained as this pathway was deemed
unsuitable for future use.

[Compound 2-23] A stirred solution 0.3074 g (2.63 mmol) of the hydrochloride salt of βhydroxyluecine with 0.4200 g (4.90 mmol) NaHCO3 in 5.8 mL H2O was brought to 0 °C. To this
stirring solution was added 0.5836 g (2.67 mmol) Boc2O dissolved in 2.2 mL THF. The reaction
was allowed to stir and reach room temperature overnight. After 18 hours, the reaction was
diluted with H2O (30 mL), and then washed with EtOAc (2x30 mL). The organic layer was then
back extracted with saturated NaHCO3 (3x25 mL). The combined aqueous layers were then
acidified to pH = 2 with 1 M HCl and extracted with EtOAc (3x30 mL). The combined organic
layers were then dried with MgSO4 and concentrated in vacuo to give 0.3613 g (87% yield)
compound 2-23 as a white foaming oil that was used without further purification.
1

H NMR (500 MHz, Chloroform-d) δ 5.68 (d, J = 9.4 Hz, 1H), 4.44 (d, J = 9.3 Hz, 1H), 3.78 –

3.72 (dd, 1H), 1.78 – 1.71 (m, 1H), 1.43 (s, 9H), 1.01 (d, J = 6.6 Hz, 3H), 0.93 (d, J = 14.2, 6.7
Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 178.67, 159.21, 82.80, 82.79, 58.67, 33.80,
33.40, 30.97, 30.66, 21.93, 21.53. Full characterization has been previously reported.1
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[Compound 2-24] The reaction was set up according to General Procedure: Lactone
Formation. The crude product was then purified by flash chromatography (silica gel, 80%
Hexane: 20% EtOAc) to give 0.3739 g (77% yield) of compound 2-24 as a white solid.
1

H NMR (300 MHz, Chloroform-d) δ 5.48 (dd, J = 9.3, 5.7 Hz, 1H), 5.41 (d, 1H), 4.22 (dd, J =

10.4, 5.7 Hz, 1H), 2.03 – 1.84 (m, 1H), 1.45 (s, 9H), 1.08 (d, J = 6.5 Hz, 3H), 0.91 (d, J = 6.6 Hz,
3H); 13C NMR (151 MHz, cdcl3) δ 169.80, 154.43, 82.85, 81.13, 59.18, 28.64, 28.64, 28.10,
28.10, 18.41, 17.05. Full characterization of compound 2-24 was not obtained as this pathway
was deemed unsuitable for future use.

[Compound 2-25] The reaction was set up according to General Procedure: Lactone
Formation. The crude product was then purified by flash chromatography (silica gel, 80%
Hexane: 20% EtOAc) to give 0.3412 g (75% yield) of compound 2-25 as a white solid.
1

H NMR (300 MHz, Chloroform-d) δ 5.50 (d, J = 5.8 Hz, 2H), 4.25 (dd, J = 10.2, 5.6 Hz, 1H),

3.74 (s, 3H), 1.91 (dp, J = 10.3, 6.6 Hz, 1H), 1.09 (d, J = 6.5, 0.9 Hz, 3H), 0.92 (d, J = 6.6, 0.9
Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 169.70, 156.08, 82.82, 59.53, 53.05, 28.60,
18.46, 17.26. Full characterization of compound 2-25 was not obtained as this pathway was
deemed unsuitable for future use.
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[Compound 2-26] A stirred solution 0.3500 g (1.90 mmol) of the hydrochloride salt of βhydroxyleucine with 0.4789 g (5.70 mmol) NaHCO3 in 6 mL H2O was brought to 0 °C. To this
stirring solution was added 6 mL THF followed by 1.1 mL (11.4 mmol) ethyl chloroformate in
three 0.35 mL portions over the next 30 minutes. The reaction was allowed to stir and reach
room temperature overnight. After 20 hours, the reaction was diluted with H2O (30 mL), and
then washed with EtOAc (2x30 mL). The organic layer was then back extracted with saturated
NaHCO3 (3x25 mL). The combined aqueous layers were then acidified to pH = 2 with 1 M HCl
and extracted with EtOAc (3x30 mL). The combined organic layers were then dried with MgSO4
and concentrated in vacuo to give 0.0.3586 g (86% yield) compound 2-26 as a clear foaming oil
that was used without further purification.
1

H NMR (300 MHz, Chloroform-d) δ 6.04 (d, J = 9.4 Hz, 1H), 4.71 – 4.60 (d, 1H), 4.30 – 4.21

(q, 2H), 3.90 (dd, J = 9.5 Hz, 1H), 1.89 (m, 1H), 1.37 (t, J = 7.1 Hz, 3H), 1.17 – 1.11 (d, 3H),
1.04 (d, J = 6.6 Hz, 3H).

C NMR (151 MHz, Chloroform-d) δ 175.71, 157.29, 77.42, 61.47,

13

56.13, 30.64, 19.13, 18.78, 14.35. Full characterization of compound 2-26 was not obtained as
this pathway was deemed unsuitable for future use.
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[Compound 2-27] The reaction was set up according to General Procedure: Lactone
Formation. The crude product was then purified by flash chromatography (silica gel, 80%
Hexane: 20% EtOAc) to give 0.2545 g (77% yield) of compound 2-27 as a white solid.
1

H NMR (500 MHz, Chloroform-d) δ 5.65 (d, J = 8.5 Hz, 1H), 5.51 (d, J = 9.4, 5.9 Hz, 1H), 4.24

(dd, J = 10.3, 5.9 Hz, 1H), 4.20 – 4.12 (q, 2H), 1.92 (m, J = 10.3, 6.7 Hz, 1H), 1.30 – 1.23 (t,
3H), 1.08 (d, J = 6.5 Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ
169.48, 155.47, 82.66, 62.03, 59.42, 28.63, 18.39, 17.19, 14.38. Full characterization of
compound 2-27 was not obtained as this pathway was deemed unsuitable for future use.

[Compound 2-28] The reaction was set up according to General Procedure: Lactone
Formation. The crude product was then purified by flash chromatography (silica gel, 80%
Hexane: 20% EtOAc) to give 0.2991 g (64% yield) of compound 2-28 as a white solid.
1

H NMR (500 MHz, Chloroform-d) δ 7.39 – 7.29 (m, 5H), 5.86 (d, J = 8.7 Hz, 1H), 5.45 (dd, J =

8.8, 5.8 Hz, 1H), 5.12 (s, 2H), 4.83 (m, J = 6.3 Hz, 1H), 1.42 (d, J = 6.1 Hz, 3H). 13C NMR (126
MHz, cdcl3) δ 171.63, 158.13, 138.21, 131.31, 131.31, 131.31, 130.90, 130.81, 77.52, 70.49,
63.01, 17.60. Full characterization of compound 2-28 was not obtained as this pathway was
deemed unsuitable for future use.
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[Compound 2-29]
The reaction was set up according to General Procedure: Lactone Formation. The crude product
was then purified by flash chromatography (silica gel, 80% Hexane: 20% EtOAc) to give 0.2983
g (64% yield) of compound 2-29 as a clear oil.
1

H NMR (500 MHz, Chloroform-d) δ 7.46 – 7.38 (m, 3H), 7.28 (m, J = 6.1 Hz, 2H), 5.81 – 5.72

(m, 2H), 4.86 (d, J = 9.4 Hz, 1H), 1.33 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 171.92, 156.73,
135.80, 131.68, 131.61, 131.57, 128.43, 83.76, 80.35, 64.95, 30.98, 30.90, 30.67, 29.94. Full
characterization of compound 2-29 was not obtained as this pathway was deemed unsuitable for
future use.

[Compound 2-30]
The reaction was set up according to General Procedure: Lactone Formation. The crude product
was then purified by flash chromatography (silica gel, 80% Hexane: 20% EtOAc) to give 0.1144
g (55% yield) of compound 2-30 as a white solid.
1

H NMR (500 MHz, Chloroform-d) δ 5.51 (d, J = 8.3 Hz, 1H), 5.42 (dd, J = 8.7, 5.9 Hz, 1H),

4.85 (dq, J = 6.2 Hz, 1H), 1.45 (s, 12H). 13C NMR (151 MHz, Chloroform-d) δ 169.46, 154.58,
81.10, 74.97, 60.00, 28.09, 14.86. Full characterization of compound 2-30 was not obtained as
this pathway was deemed unsuitable for future use.
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Chapter Three: Simplified Analogs
Conclusions and Future Directions
3.1 First Generation Synthesis

Figure 3.1 – WU-07047 & FR900359
This project began with the successful synthesis of analog WU-07047 (Figure 3.1), also
highlighted in Figure 1.4. This analog was then screened in a receptor-assisted GTPγS
nucleotide exchange assay to determine its inhibitory activity in comparison to the natural
product FR.1-3 In this assay the uptake of GTP was observed using GTPγS, a γ-phosphate
radiolabeled with 35S. As an inactive G protein is bound to GDP (Figure 1.1), observing an
uptake in GTP is indicative of the activation of this cell signaling pathway. We hoped to observe
less of an uptake of GTP, indicating the successful binding and subsequent inactivation of this
cell signaling pathway. When compared to the commercially available compound UBO-QIC,
now referred to as FR900359 (Figure 3.1) there are two noteworthy observations regarding WU07047. First, WU retained selectivity towards only one G protein and successfully inhibited
nucleotide exchange on Gαq in a concentration dependent manner. Second, while WU was able
60

to inhibit nucleotide exchange with similar efficacy as FR (up to 40% inhibition of nucleotide
exchange) it was much less potent (Figure 3.2).4

Figure 3.2 – Receptor-assisted GTPγS Nucleotide Exchange Assay4
We believe this loss is due to the simplification of the top and bottom bridges to alkyl
chains. Efforts were first made to install an intramolecular hydrogen bond found in the natural
product to the simplified analog.

3.2 Top Bridge Amide Bond Installation
In the first attempt to return biological activity to a simplified analog, Dr. Derek Rensing
chose to install an amide bond within the simplified alkyl chain of the top bridge in WU-07047.5
This decision was made based on an intramolecular hydrogen bond that appears to be important
in the crystal structure of YM bound to its active site in Gαq. This hydrogen bond donor is
highlighted red in both FR and the new, simplified analog WU-09060 (Figure 3.3). The intent
was to stabilize the bound conformation of the analog by returning this intramolecular hydrogen
bond and in doing so improve binding of the analog to the receptor.
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Figure 3.3 – FR900359 & WU-09060
Significant challenges were faced when assembling this analog, inevitably leading to the
analog WU-09060 in only a 1.8% overall yield, with a longest linear reaction sequence of 10
steps. When tested for its ability to inhibit exchange of GDP for GTP on Gαq the analog installed
with the intramolecular hydrogen bond proved to be worse than the first simplified analog WU07047 (Figure 3.5). Due to the difficulties associated with the synthesis of WU-09060 and the
loss of potency and efficacy in the biological assay, this analog is no longer being pursued. The
observation that a change within the top bridge of the simplified analogs did not lead to a
significant change in biology is consistent with the suggestion that the top bridge of the molecule
may not play a significant role in binding. As mentioned in Section 1.2, this portion of the
molecule appears to reside outside of the active site in the natural product – receptor complexes
forwarded to date. This knowledge, in addition to information currently available in the
literature, has led to the decision to install the “bottom bridge” of the macrocycle (discussed in
Chapter 4) in an effort to improve the binding and efficacy of the simplified analogs.
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3.3 Inhibition of Vasoconstriction by YM & WU
In addition to the biological studies underway in our collaboration with the Blumer lab
studying G protein signaling and its relationship to uveal melanoma, our collaborators in the
Osei-Owusu lab are exploring the use of our simplified analogs in connection with the role of
Gαq/11 in vasoconstriction. 6 Alone these lines, calcium influx through voltage-gated L-type
calcium channels (LTCC) and receptor-operated calcium channels are critical for
vasoconstriction, and it appears that Gαq/11 plays a critical role in regulating these cell signaling
events. As such, efforts have been made to determine the ability of Gαq/11 inhibitors to block
the LTCC. This has led to a unique observation. Both YM and WU exhibit an inhibitory effect
on calcium influx by partially targeting the LTCC itself, in addition to Gαq/11, thereby blocking
vasoconstriction. This is in contrast to FR, which blocks vasoconstriction by only targeting
Gαq/11, with no off-target binding at the LTCC. Efforts to synthesize new analogs to probe this
difference between activity are currently underway and will be discussed in Section 3.6.

3.4 Alternative Binding Mode of WU
The observation that YM and WU partially block vasoconstriction through targeting the
LTCC led to a molecular modeling study comparing the critical residues within the hydrophobic
pocket of Gαq/11 to that of the LTCC. It was found that there was significant homology between
the two receptors, potentially accounting for YM and WU’s ability to block vasoconstriction by
binding to the LTCC. Interestingly, while both YM and WU bind to the LTCC, molecular
modeling suggests that the two molecules bind the receptor with distinct binding motifs (Figure
3.4).6 In fact, relative to YM, the WU analog is completely inverted in the binding pocket.
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Figure 3.4 – WU-07047 & YM-254890 Binding6
In the case of YM, the phenyl ring of the phenylacetic acid (DPla6) binds in a
hydrophobic pocket near amino acid residue Y168. In comparison, the bound WU analog places
the phenyl ring towards amino acid residue F203, and the isopropyl group of the β-hydroxy
leucine tail is oriented towards Y168. These observations have led to the projection of a variety
of analogs to probe this unique binding motif. Is it possible to exploit the binding motif displayed
above to develop an analog that is selective towards the LTCC receptor in the same fashion that
FR is selective towards only Gαq? These analogs will be discussed further detail in Section 3.6.

3.5 Methyl Carbamate Protecting Group
The use of a methyl chloroformate as a replacement for the acetate group on the βhydroxy leucine tail was chosen in the hopes that it would be biologically tolerated thereby
eliminating the need exchange protecting groups in the final steps of the synthesis. As previously
mentioned, the use of an acetyl protecting group on an amino acid derivative is not compatible
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with an esterification reaction of the acid and hence cannot be used to add the β-hydroxy leucine
side chain. The hypothesis that the methyl carbamate would be tolerated was based upon the
observation that one of the two differences between YM and FR occurs at this site. The FR
natural product has a propionate group at this position, and a variety of analogs of FR have been
isolated with groups larger than a propionate appended to the amine in the β-hydroxy leucine
side chain.7

Figure 3.5 – Comparison of FR to WU Analogs
Fortunately, not only did the use of a methoxycarbamate protecting group result in an
improvement of overall yields, but it also improved the efficacy and potency of the analog
relative to the first simplified analog WU-07047. This new analog, Compound 2-17, is labeled
WU_06047 in Figure 3.5. In this case, the efficacy of the simplified analogs was compared to
that of FR using an agonist-induced Ca2+ flux assay.8 In this assay HEK2923 cells were
transfected with a Twitch 2B Ca2+ Fret reporter. The cells were then treated with FR, an FR
analog, or a vehicle for three hours, and then stimulated with the Gq-coupled GPCR agonist
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carbachol. The recorded changes in Twitch 2B fluorescence and FRET are reported in Figure
3.5. While the analog WU_06047 is a step in the right direction, we are still far from the efficacy
found in the natural product FR.

3.6 Simplified Analogs from Molecular Modeling
Based upon some of the observations discussed in Section 3.4, there are a handful of
analogs of interest that are currently in development. There is significant interest in probing the
hydrophobic pocket the phenyl ring within the right-hand portion of the molecules (highlighted
red in Figure 3.6). Analogs in development will have hydroxy or methoxy substituents in either
the ortho, meta, or para positions.

Figure 3.6 – Simplified Analogs from Molecular Modeling
Due to the unique inverted binding mode to the LTCC predicted for analog WU-07047,
an analog containing a phenyl group in place of an isopropyl group of the β-hydroxyleucine tail
is being synthesized by Dr. Ruby Krueger in our lab. Dr. Krueger has been able to rapidly
assemble the core ring scaffold and is currently at the final esterification reaction necessary to
add the β-hydroxy leucine side-chain. Her ability to rapidly reach this point in the synthesis
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within several weeks of joining our lab is further evidence of the success and reproducibility of
our second-generation synthesis.

3.7 Simplified Analogs to Improve Efficacy
The second-generation synthesis has given us rapid access to analogs to probe distinct
portions of the simplified analogs. Two such analogs that may significantly improve activity with
few changes in our synthetic strategy are outlined in Figure 3.7. According to current SAR
studies, the exchange of the NMe-amide labeled 1 to an amide results in a 670-fold loss in
potency. Similarly, the exchange of the NMe-amide labeled 2 resulted in a nearly 500-fold loss
in potency.9

Figure 3.7 – Recommended Analogs Based on SAR
The installation of the NMe-amides within the structure should in theory require only one
additional step to install each NMe-amine (Figure 3.8). The methylation of the amine within the
“top bridge” labeled 1 can be synthesized by treating Boc-8-aminocaprylic acid with methyl
iodide and sodium hydride. These conditions will mimic the methylation conditions used in the
synthesis of NMe-OMe-Thr in our central building block (Scheme 3.1).9,10 The installation of
the NMe-amide within the “bottom bridge” labeled 2 could be readily synthesized from
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Compound 2-11. In our second-generation synthesis Compound 2-11 was protected with an
allyl ester (Scheme 2.3). In this case, it may be plausible to use standard coupling conditions to
couple the carboxylic acid with an N-allylmethylamine. Upon synthesis of these two molecules,
the synthetic route to the final product would not vary from our second-generation synthesis.

Figure 3.8 – N-Methyl Synthetic Strategy

3.8 Conclusions from Simplified Analogs

Figure 3.9 – Second Generation Synthesis
The use of our second-generation synthesis has played a key role in the development and
scaling of new analogs. The key step, the addition of the β-hydroxy leucine to the macrocycle
last (Figure 3.9), provided the first evidence that this esterification can be accomplished in the
final stage of a synthesis. A key component of this second-generation synthesis is the use of a
methyl carbamate protecting group in place of the acetyl group located on the β-hydroxyleucine
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tail in the natural product. At present, this synthetic route has produced three different analogs,
and is still in use for the rapid synthesis of chemical probes (some in as little as 2-3 weeks). This
overall strategy will continue to be employed for the development of all new analogs to probe the
GPCR many of which were discussed above. With the second-generation strategy in place, we
have turned our attention to returning efficacy and potency to our simplified analogs and the
development of analogs that are selective inhibitors of voltage-gated L-type calcium channels.
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Chapter Four: Returning Activity through
Installation of the Bottom Bridge
4.1 A New Retrosynthetic Analysis
As more information has become available, the X-ray crystal driven hypothesis that only
the left- and right-hand portions of the natural product that make direct contact with Gαq are
necessary for the activity of the molecule has been shown to be incorrect. This has been
confirmed through the synthesis of our simplified analogs that retain selectivity towards Gαq, but
do not have either the same potency or efficacy as the natural product. This knowledge combined
with the work of others suggests the importance of the “bottom bridge”.1,2 In these structure
activity studies, changes within the bottom bridge have had a significant impact on the potency
and efficacy of the analog. For example, exchanging the NMe-OMe-Thr for a threonine within
central building block (Figure 4.1) resulted in nearly a 500-fold loss in potency. Whether
through direct contact with the active site, or through conformational constraint, it appears that
incorporation of an intact portion of the macrocycle (stretching from DhAla to β-hydroxyleucine)
will be necessary to improve binding the activity of the analogs being scaled.

Figure 4.1 – “Bottom Bridge” Retrosynthetic Analysis
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From the lessons learned from our second-generation synthesis discussed in Chapter 2,
the plan for construction of a more functionalized analog called for the addition of the β-hydroxy
leucine tail last, and a ring closing metathesis strategy to tie together the macrocycle (Figure
4.1). In the retrosynthetic analysis, following removal of the β- hydroxy leucine tail, the
synthesis breaks down to the construction and subsequent assembly of three major building
blocks. The right-hand portion is a coupled product of N-allylamine and a phenylacetic acid
derivative. The central portion is a known building block that is a dipeptide made from a
demethylated threonine and an N-acylated threonine.1 The left-hand portion of our molecule is a
coupled product of a β-hydroxy leucine to a carboxylic acid derivative containing a terminal
alkene. The plan called for assembly of these three molecules required standard coupling or
esterification procedures, with the formation of the macrocycle using a ring closing metathesis
reaction. This convergent route will give us rapid access to multiple analogs. With that backdrop,
we begin with the reported synthesis of the bottom bridge and the challenges associated with its
assembly.

4.2 Synthesis of the Bottom Bridge

Scheme 4.1 – Central Building Block Synthesis
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The synthesis of the central building block was repeated following current literature
protocol.1,2 The synthesis began with Boc protected threonine that was treated with an excess of
sodium hydride (5 eq.) and methyl iodide (10 eq.). This afforded compound 3-3 as an
inseparable mixture of NMe-OMe-Thr and β-elimination product in a ratio between [3-1] and [41] determined by proton NMR integration. This material was purified following coupling to
previously synthesized compound 3-1. In our hands, this product could be synthesized in a 27%
isolated yield over three steps (Scheme 4.1). While the structure of the product was confirmed, it
could not be readily carried forward in subsequent reactions to assemble the larger acyclic
structure. Yet another β-elimination plagued synthetic transformations using this building block
as starting material (Figure 4.2). For example, while compound 3-4 can be stored below room
temperature to significantly slow the β-elimination, this decomposition occurs during
purification, and in the presence of base in subsequent reactions.

Figure 4.2 – β-Elimination Decomposition Products
Despite the evidence of this decomposition pathway efforts were made to push forward in
the synthesis. While we were able to handle these molecules gently enough to minimize this
decomposition as evidence of the synthesis of compound 3-13 in 66% yield across two steps
(Scheme 3.2). As we carried compound 3-13 forward to the subsequent Boc deprotection and
coupling to the left-hand portion we isolated further evidence of β-elimination (Figure 4.3).
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Scheme 4.2 – Central Building Block Mitsunobu Reaction

Figure 4.3 – Further Evidence of β-Elimination
At this point it had become clear that the β-elimination needed to be addressed
immediately because similar reactions will occur in all subsequent steps of this reaction sequence
prior to the macrocyclization. One simple option that we hoped would slow this β-elimination,
was to change the N-acetyl protecting group so that the nitrogen would not be as electronwithdrawing, a change that would decrease the acidity of the α-proton involved in the
elimination. Given our prior experience with the second-generation synthesis, we chose to
protect this amine with a methyl carbamate, at the time hoping this change in the final analog
would once again be tolerated biologically. This will allow us to avoid an exchange of protecting
groups to that of the acetate found in the natural product late in the synthesis.
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4.3 Avoiding the β-Elimination of the Bottom Bridge

Scheme 4.3 – Modified Central Building Block Synthesis
The synthesis of the modified central building block (the “bottom bridge” in the natural
product) began in a similar fashion as reported above (Scheme 4.3).1,2 The first modified amino
acid required for the central building block was synthesized from the commercially available
benzyl ester of the threonine oxalate salt. This substrate was chosen due to difficulties isolating
the methyl carbamate protected acid of threonine itself from the aqueous layer following work
up. The methyl carbamate protected compound 3-2 was isolated in an 84% yield underwent the
subsequent esterification reaction with the previously synthesized NMe-OMe-Thr (compound 33), using catalytic DMAP and no additional stoichiometric base in an effort to reduce the amount
of β-elimination side product generated. This reaction afforded a 75% yield of compound 3-5.
When compared to the overall yield across the same steps containing the N-acyl amine, there
was an improvement in yield observed from 27% to 42% yield over three steps, with less
evidence of elimination product. It appears that the use of the modified protecting group strategy
did aid the synthesis. With that, attention was turned toward the assembly of the rest of the
macrocycle.
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4.4 Synthesis of the Right-Hand Building Block

Scheme 4.4 – Right-Hand Piece Synthesis
The synthesis of the right-hand building block was accomplished through a standard
amide coupling procedure with HATU and DIPEA (Scheme 4.4). In this case, the
thermodynamic amide product, compound 3-6, was isolated in an 82% yield. A slight excess of
our phenylacetic acid derivative (1.2 eq.) was used, as any uncoupled material would be lost in
aqueous work up. With the right-hand building block in hand we could now turn our attention to
the final piece of the macrocycle, the left-hand building block.

4.5 Synthesis of the Left-Hand Building Block

Scheme 4.5 – Left-Hand Building Block Synthesis
They synthesis of the left-hand building block began in a similar fashion to our previous
synthesis (Scheme 4.5). To this end, we were able to activate the carboxylic acid derivative as a
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mixed anhydride. Upon treatment of the mixed anhydride with β-hydroxy leucine in 1 M NaOH,
compound 3-7 was generated in an 81% yield. The intent was to carry this material forward to
the coupling of the NMe-threonine within the central building block. However, this coupling
reaction resulted in poor yields of the desired amide product.

Figure 4.4 – Evidence of Esterification
In our second-generation synthesis, it was possible to isolate the thermodynamic amide
product in the presence of a free hydroxyl group (Scheme 2.4). In this case however, it appears
that the acylation of the methyl amine is much too slow. As evidence, the major product isolated
shown in Figure 4.4 was clearly evidence of the β-elimination we have seen time and time again.
For this β-elimination reaction to occur, the free hydroxyl group must first be converted into a
leaving group, in this case an ester that is a dimer of compound 3-7. Evidence of precisely this
β-elimination was first highlighted in Figure 2.2. The isolation of this product made it clear we
must devise a protecting group strategy as the free hydroxyl group is no longer an innocent
bystander.

77

Scheme 4.6 – Left-Hand Protecting Group Strategy
Upon synthesis of compound 3.7, the protecting group strategy began with treating the
carboxylic acid with NaHCO3 and allyl bromide to afford the allyl ester (Scheme 4.5). This allyl
ester protecting group was chosen over that of a benzyl protection group used earlier in the
synthesis, due to the deprotection conditions. The hydrogenation reaction most typically used to
remove a benzyl group would also reduce the alkene necessary for the future ring closing
metathesis, where deprotection of the alloc group with Pd(Ph3)4 should not touch the alkene.
Following protection of the carboxylic acid, we protected the free hydroxyl group with TBDMStriflate, followed by subsequent deprotection of the alloc group. This afforded our appropriately
protected left hand piece, compound 3.10, in a 71% yield. With the three major pieces of our
synthetic route in hand, we could now turn our attention to the assembly of the macrocycle.
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4.6 Assembling the Macrocycle
With the three major components of our macrocycle in hand, we had a choice to make.
Should we build the macrocycle from left to right, or right to left? The decision was made to
couple the central building block to the right-hand piece first, due challenges removing
triphenylphosphine oxide (a byproduct of the Mitsunobu reaction) from the desired product. We
felt that it was best to ensure this by-product was removed before assembly of the whole
molecule.

Scheme 4.7 – Assembly of the Macrocycle
With this in mind, the previously synthesized central building block was treated with
standard hydrogenation conditions to cleave the benzyl protecting group, affording a 90% yield
of the acid that was carried forward without further purification. The isolated carboxylic acid
then underwent the Mitsunobu reaction with the previously synthesized right-hand piece,
affording compound 3-14 in an 88% yield, with no evidence of elimination product present. It
appears without the presence of a strong base, the β-elimination does not occur as readily with
the use of the methylcarbamate protecting group.
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Figure 4.5 – Challenges Faced with the N-Methyl Coupling
This is the current stopping point for this approach to the synthesis due to significant
challenges faced in coupling the N-Me amine (following Boc deprotection) to the left-hand
portion of the molecule (Figure 4.5). Despite our efforts to devise a suitable protection strategy
for the left-hand portion of our molecule, further evidence of the problematic β-elimination was
isolated, with only trace evidence of coupled product observed in the proton NMR. Future
strategies that may be used to successfully assemble this molecule will be discussed Chapter 5.
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4.8 Experimental Procedures

[Compound 3-1] To a flame dried round bottom flask was added 0.5041 g (1.67 mmol) LThreonine benzyl ester oxalate with 0.1485 g (1.75 mmol) NaHCO3. The flask was then brought
to 0 °C and stirred in 5 mL THF with 5 mL H2O. To the stirring solution was added 0.16 mL
(1.67 mmol) Acetic anhydride. The pH of the reaction was then adjusted to 10 using 1 M NaOH
solution, and was allowed to stir and reach room temperature overnight. The reaction was then
diluted with 30 mL H2O and extracted with EtOAc (3x35 mL). The combined organic layers
were then dried with MgSO4 and concentrated in vacuo to afford 0.3118 g (74% yield) of
compound 3-1 as a white solid. This product was carried forward without any further
purification.
1

H NMR (300 MHz, Chloroform-d) δ 7.33 (d, J = 2.7 Hz, 5H), 6.67 (d, J = 8.9 Hz, 1H), 5.16 (s,

2H), 4.60 (dd, J = 9.0, 2.5 Hz, 1H), 4.34 (dq, J = 6.4, 3.2 Hz, 1H), 2.03 (s, 3H), 1.17 (d, J = 6.4
Hz, 3H); δ 13C NMR (126 MHz, cdcl3) δ 170.97, 170.78, 135.22, 128.66, 128.66, 128.51,
128.19, 128.19, 77.28, 77.03, 76.77, 68.06, 67.36, 57.35, 23.09, 20.02. Full characterization of
compound 3-1 was not obtained as this pathway was deemed unsuitable for future use.
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[Compound 3-2] To a flame dried round bottom flask was added 0.499 g (1.67 mmol) LThreonine benzyl ester oxalate with 0.3506 g (4.17 mmol) NaHCO3. The flask was then brought
to 0 °C and stirred in 6 mL THF with 6 mL H2O. To this stirring solution was added 0.65 mL
(8.35 mmol) Methyl chloroformate dropwise. The reaction was allowed to stir and reach room
temperature overnight. After 20 hours, the reaction was diluted with 50 mL EtOAc and washed
with saturated NaHCO3 (3x30 mL). The combined aqueous layers were then back extracted with
EtOAc (2x20 mL). All organic layers were then dried with MgSO4 and concentrated in vacuo to
afford 0.3755 g (84% yield) of compound 3-2 as a clear oil. This product was carried forward
without any further purification.
1

H NMR (500 MHz, Chloroform-d) δ 7.37 – 7.25 (m, 5H), 5.99 (d, J = 9.3 Hz, 1H), 5.15 (s, 2H),

4.37 – 4.28 (m, 2H), 3.64 (s, 3H), 1.20 (d, J = 6.5 Hz, 3H); 13C NMR (126 MHz, Chloroform-d)
δ 13C NMR (126 MHz, cdcl3) δ 173.93, 160.30, 137.99, 131.24, 131.04, 130.98, 130.78, 130.78,
80.17, 79.91, 79.65, 70.55, 69.92, 62.22, 55.19, 22.55. Full characterization of compound 3-2
was not pursued as this synthetic route is still in development.

[Compound 3-3] To a flame dried round bottom flask was added 1.0010 g (4.56 mmol) Boc-Lthreonine with 0.90522 g (22.6 mmol) NaH 60% dispersion in mineral oil. The flask was then
brought to 0 °C before addition of 28 mL THF. To this stirring solution 2.8 mL Iodomethane was
then carefully added. The reaction was allowed to stir and reach room temperature overnight.
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After 24 hours, the flask was diluted with 50 mL DI H2O and concentrated in vacuo. The
remaining aqueous layer was then brought to pH=3 with 1 M HCl, and was then extracted with
EtOAc (3x35 mL). The crude product was then purified by flash chromatography (silica gel,
70% Hexane: 30% EtOAC) to afford 0.7574 g (67% yield) of compound 3-3 as a clear oil.
Trace impurity inseparable and was carried forward to the subsequent esterification.
1

H NMR (500 MHz, Chloroform-d) δ 7.03 – 6.83 (q, 1H), 4.95 – 4.61 (d, 1H), 4.02 (dq, J = 39.4,

5.9 Hz, 1H), 3.36 – 3.29 (s, 3H), 3.01 – 2.94 (s, eH), 1.81 (d, J = 7.1, 2.4 Hz, 1H), 1.53 – 1.40 (s,
9H), 1.18 (d, J = 10.2, 6.3 Hz, 3H); 13C NMR (126 MHz, cdcl3) δ 178.23, 159.80, 83.13, 79.12,
66.04, 59.90, 37.99, 30.96, 30.94, 30.80, 17.85. Full characterization of compound 3-3 has been
previously reported.1

[Compound 3-4] A flame dried flask was brought to 0 °C with 0.2030 g (1.10 mmol)
compound 3-1, 0.3789 g (1.98 mmol) EDC, and 0.0273 g (0.22 mmol) DMAP. To this flask was
added 0.3264 g (1.32 mmol) of compound 3-3 in 16 mL DCM. The reaction was allowed to stir
and reach room temperature overnight. After 48 hours, the reaction was diluted with 50 mL
DCM. The organic layer was washed with saturated NaHCO3 (3x30 mL). The combined aqueous
layers were then back extracted with DCM (2x20 mL). All organic layers were then dried with
MgSO4 and concentrated in vacuo. The crude product was then purified by flash chromatography
(silica gel, 50% Hexane: 50% EtOAC) to afford 0.2710 g (54% yield) of compound 3-4 as a
clear oil.
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1

H NMR (300 MHz, Chloroform-d) δ 7.32 – 7.24 (m, 5H), 5.39 (dq, J = 6.3, 2.8 Hz, 1H), 5.13 –

5.00 (m, 3H), 4.87 (d, 1H), 3.85 (dq, J = 6.2 Hz, 1H), 3.20 (s, 3H), 2.82 (s, 3H), 2.01 (s, 3H),
1.39 (s, 9H), 1.27 (d, 3H), 1.08 (d, J = 6.1 Hz, 3H). Full characterization of compound 3-4 was
not obtained as this pathway was deemed unsuitable for future use.

[Compound 3-5] A flame dried flask was brought to 0 °C with 0.6868 g (2.57 mmol)
compound 3-2, 0.6940 g (3.63 mmol) EDC, and 0.0785 g (0.64 mmol) DMAP. To this flask was
added 0.8972 g (3.63 mmol) of compound 3-3 in 16 mL DCM. The reaction was allowed to stir
and reach room temperature overnight. After 48 hours, the reaction was diluted with 50 mL
DCM. The organic layer was washed with saturated NaHCO3 (3x30 mL). The combined aqueous
layers were then back extracted with DCM (2x20 mL). All organic layers were then dried with
MgSO4 and concentrated in vacuo. The crude product was then purified by flash chromatography
(silica gel, 80% Hexane: 20% EtOAC) to afford 0.9616 g (75% yield) of compound 3-5 as a
clear oil.
1

H NMR (500 MHz, Chloroform-d) δ 7.40 – 7.30 (m, 5H), 5.56 – 5.42 (m, 2H), 5.14 (s, 2H),

4.86 (d, J = 5.0 Hz, 1H), 3.91 (dq, J = 17.7, 11.9, 6.1 Hz, 1H), 3.71 (s, 3H), 3.26 (s, 3H), 2.90 (s,
3H), 1.46 (s, 9H), 1.36 (d, 3H), 1.14 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, cdcl3) δ 172.19,
171.78, 159.80, 159.44, 137.63, 131.28, 131.26, 131.15, 131.10, 131.06, 82.66, 73.87, 70.42,
70.26, 64.72, 60.29, 59.62, 55.22, 35.44, 30.95, 30.95, 30.81, 19.59, 17.57. Full characterization
of compound 3-5 was not pursued as this synthetic route is still in development.
85

[Compound 3-6] To a flame dried flask was added 0.5015 g (3.00 mmol) Phenylactic acid with
1.4050 g (3.70 mmol) HATU which were then set to stir in 20 mL DMF. To this stirring solution
was added 0.20 mL (2.50 mmol) N-allyl amine and 1.0 mL (6.00 mmol) DIPEA. The reaction
was allowed to stir at room temperature overnight. After 20 hours, the reaction was diluted with
50 mL EtOAc and washed with saturated NaHCO3 (3x30 mL). The combined aqueous layers
were then back extracted with EtOAc (2x20 mL). All organic layers were then dried with MgSO4
and concentrated in vacuo. The crude product was then purified by flash chromatography (silica
gel, 60% Hexane: 40% EtOAC) to afford 0.4493 g (82% yield) of compound 3-6 as a clear oil.
1

H NMR (300 MHz, Chloroform-d) δ 7.34 – 7.18 (m, 5H), 6.79 (t, J = 6.1 Hz, 1H), 5.73 (m,

1H), 5.14 – 5.04 (m, 2H), 4.26 (t, J = 8.5, 4.9, 3.8 Hz, 1H), 3.81 (m, J = 6.0, 4.6, 1.6 Hz, 2H),
3.18 (dd, J = 13.9, 3.8 Hz, 1H), 2.84 (dd, J = 13.9, 8.3 Hz, 1H); 13C NMR (126 MHz, cdcl3) δ
176.42, 140.26, 136.46, 132.32, 131.97, 130.86, 129.11, 118.76, 75.33, 43.91, 41.18. Full
characterization of compound 3-6 was not pursued as this synthetic route is still in development.

[Compound 3-7] A stirred solution of 0.37 mL (2.73 mmol) 6-Heptenoic acid and 0.33 mL
(2.97 mmol) of 4-methylmorpholine in 8 mL THF was brought to -10 °C. To the stirring solution
0.37 mL (2.86 mmol) isobutyl chloroformate was added and maintained at -10 °C for 30
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minutes. The reaction was allowed to warm to 0 °C at which time 0.6423 g (3.51 mmol) of the
hydrochloride salt of β-hydroxyluecine in 5.5 mL of 1 M NaOH was added. The reaction was
allowed to warm to room temperature overnight and stirred for 24 hours. The reaction was then
diluted with 30 mL H2O, and washed with EtOAc (2x25 mL). The combined organic layers were
then extracted with saturated NaHCO3 (3x25 mL). All aqueous layers were combined and
acidified to pH=2 with 1 M HCl and extracted with EtOAc (3x30 mL). The combined organic
layers were then dried with MgSO4 and concentrated in vacuo to give 0.5695 g (81% yield) of
compound 3-7 as a white foaming oil that was carried forward without further purification.
1

H NMR (500 MHz, Chloroform-d) δ 6.87 (d, J = 7.8 Hz, 1H), 5.84 – 5.75 (m, 1H), 5.04 – 4.94

(m, 2H), 4.75 (d, J = 8.9, 1.9 Hz, 1H), 3.82 (dd, J = 9.3, 1.9 Hz, 1H), 2.33 (t, J = 27.5, 7.4 Hz,
2H), 2.12 – 2.02 (m, 2H), 1.74 – 1.62 (m, 3H), 1.49 – 1.38 (m, 2H), 1.02 (d, J = 6.6 Hz, 3H),
0.90 (d, J = 6.7 Hz, 3H).

C NMR (126 MHz, cdcl3) δ 181.27, 177.72, 140.99, 117.38, 57.18,
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38.74, 36.00, 33.45, 31.00, 27.76, 26.80, 21.85, 21.45. Full characterization of compound 3-7
was not pursued as this synthetic route is still in development.

[Compound 3-8] To a stirring solution of 0.3123 g (1.21 mmol) compound 3-7 with 0.4074 g
NaHCO3 (4.85 mmol) in 5.8 mL DMF was added 0.89 mL (10.3 mmol) Allyl bromide in a
dropwise fashion. The reaction was allowed to stir at room temperature overnight. After 20 hours
the reaction was diluted with 30 mL H2O, and extracted with EtOAc (3x30 mL). The combined
organic layers were then washed with saturated NaHCO3 (2x20 mL) then brine (1x20 mL). The
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organic layer was then dried with MgSO4 and concentrated in vacuo. The crude product was then
purified by flash chromatography (silica gel, 60% Hexane: 40% EtOAc) to give 0.2074 g (57%
yield) of compound 3-8 as a clear oil.
1

H NMR (300 MHz, Chloroform-d) δ 6.48 (d, J = 9.2 Hz, 1H), 6.01 – 5.68 (m, 2H), 5.42 – 5.19

(m, 2H), 5.10 – 4.85 (m, 2H), 4.83 (dt, J = 9.2, 2.0 Hz, 1H), 4.64 (dd, J = 5.8, 1.3 Hz, 2H), 3.74
(dd, J = 9.0, 2.1 Hz, 1H), 2.27 (t, J = 7.5, 1.9 Hz, 2H), 2.14 – 1.99 (m, 2H), 1.67 (m, 3H), 1.51 –
1.34 (m, 2H), 1.01 (d, J = 6.6, 1.9 Hz, 3H), 0.92 (d, J = 6.8, 2.0 Hz, 3H). 13C NMR (126 MHz,
Chloroform-d) δ 13C NMR (126 MHz, cdcl3) δ 176.07, 174.18, 141.08, 134.23, 121.43, 117.31,
80.09, 68.77, 56.77, 39.01, 36.06, 33.63, 31.04, 27.73, 21.55, 21.51. Full characterization of
compound 3-8 was not pursued as this synthetic route is still in development.

[Compound 3-9] To a stirring solution of 0.1362 g (0.45 mmol) compound 3-8 in 2.5 mL DCM
at 0 °C was added 0.26 mL (2.29 mmol) 2,6-Lutidine, followed by dropwise addition of 0.26 mL
(1.14 mmol) TBDMS-triflate. The reaction was allowed to stir and reach room temperature
overnight. After 24 hours, the reaction was quenched with 1 M HCl (20 mL). Reaction was then
extracted with DCM (3x25 mL). The combined organic layers were then washed with 1 M
KHSO4(30 mL) and brine (30 mL). The organic layer was then dried with MgSO4 and
concentrated in vacuo. The crude product was then purified by flash chromatography (silica gel,
90% Hexane: 10% EtOAc) to give 0.1736 g (92% yield) of compound 3-9 as a clear oil.
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1

H NMR (500 MHz, Chloroform-d) δ 6.18 (d, J = 9.1 Hz, 1H), 5.92 (m, 1H), 5.85 – 5.76 (m,

1H), 5.40 – 5.25 (m, 2H), 5.08 – 4.94 (m, 2H), 4.77 – 4.70 (d, 1H), 4.62 (dd, J = 4.5, 2.9, 1.4 Hz,
2H), 4.00 (dd, J = 6.5, 3.3, 1.3 Hz, 1H), 2.33 – 2.25 (t, 2H), 2.14 – 2.06 (m, 2H), 1.86 – 1.76 (m,
2H), 1.72 – 1.66 (m, 2H), 1.53 – 1.44 (m, 2H), 1.02 – 0.88 (m, 15H), 0.10 (s, 3H), 0.02 – -0.03
(s, 3H). 13C NMR (126 MHz, cdcl3) δ 175.33, 173.93, 141.06, 134.22, 121.43, 117.32, 79.60,
68.70, 56.15, 39.15, 36.07, 35.91, 30.99, 28.58, 28.31, 27.63, 21.77, 20.66, -0.93, -1.55, -2.13.
Full characterization of compound 3-9 was not pursued as this synthetic route is still in
development.

[Compound 3-10] A stirred solution of 0.0463 g (0.04 mmol) Pd(PPh3)4 in 0.7 mL of THF was
cooled to -78°C. To this was added 0.02 mL n-BuLi (0.04 mmol of a 2.5 molar solution in
hexanes) and the solution was stirred at -78 for 1 hour at which time it was added to a separate
stirred solution of 0.1696 g (0.41 mmol) compound 3-9 in 0.7 mL THF. Added immediately to
this stirring solution was 0.35 mL (4.0 mmol) Morpholine. The reaction was stirred at room
temperature for 2 hours at which time the reaction was diluted with 15 mL of diethyl ether and
organic layer washed with 1 M KHSO4 (3x15 mL) and brine (15 mL). The organic layer was
dried over MgSO4 and concentrated in vacuo. The crude product was then purified by flash
chromatography (silica gel, 70% Hexane: 30% EtOAc) to give 0.072 g (71% yield) of
compound 3-10 as a clear oil.
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1

H NMR (500 MHz, Chloroform-d) δ 6.27 (dd, J = 8.6, 2.5 Hz, 1H), 5.81 – 5.71 (m, 1H), 5.01 –

4.88 (m, 2H), 4.62 (ddt, J = 8.6, 2.7, 1.3 Hz, 1H), 4.05 – 4.00 (m, 1H), 2.26 (td, J = 7.7, 2.9 Hz,
2H), 2.03 (qdd, J = 7.0, 3.7, 1.4 Hz, 2H), 1.80 – 1.70 (m, 1H), 1.66 – 1.59 (m, 2H), 1.41 (dtd, J =
15.1, 7.3, 3.9 Hz, 2H), 0.99 (ddd, J = 9.2, 4.8, 2.1 Hz, 1H), 0.92 (dt, J = 5.1, 2.6 Hz, 2H), 0.88
(dt, J = 3.8, 2.0 Hz, 12H), 0.06 (dt, J = 2.8, 1.3 Hz, 3H), 0.00 (dd, J = 3.1, 1.1 Hz, 3H). 13C NMR
(126 MHz, cdcl3) δ 179.42, 178.33, 142.92, 119.33, 81.23, 58.30, 41.00, 37.97, 37.72, 32.87,
30.56, 30.24, 29.53, 23.60, 22.80, 22.74, 0.95, 0.24, 0.00. Full characterization of compound 310 was not pursued as this synthetic route is still in development.

[Compound 3-11] To a flame dried flak were added 0.2470 g (0.51 mmol) compound 3-4 and
0.0180 g (0.17 mmol) Pd on Carbon in 2.3 mL MeOH. The flask was then placed under positive
pressure of H2 and stirred vigorously and monitored by TLC until completion, between 6-8
hours, at which time the reaction was diluted with 50 mL MeOH. The solution was then filtered
through celite and concentrated in vacuo. The crude product, 0.1966 g (98%) compound 3-11,
was carried forward without any further purification.

[Compound 3-12] To a flame dried flak were added 0.4133 g (0.83 mmol) compound 3-5 and
0.0306 g (0.27 mmol) Pd on Carbon in 4 mL MeOH. The flask was then placed under positive
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pressure of H2 and stirred vigorously for The reaction was monitored by TLC until completion,
between 6-8 hours, at which time the reaction was diluted with 50 mL MeOH. The solution was
then filtered through celite and concentrated in vacuo. The crude product, 0.3280 g (97%)
compound 3-12, was carried forward without any further purification.

[Compound 3-13] In a flame dried round bottom flask 0.2007 g (0.51 mmol) compound 3-11
was subjected to a benzene (30 mL) azeotropic distillation to remove any trace water. To this
flask was added 0.1298 g (0.49 mmol) triphenylphosphine, followed by 1.8 mL THF. The flask
was stirred at -30 °C before addition of 0.0965 g (0.47 mmol) compound 3-6 dissolved in an
additional 1.8 mL THF, followed by dropwise addition of 0.24 mL (0.52 mmol) of a 40 wt %
solution of Diethyl azodicarboxylate in toluene. The temperature was maintained at -30 °C for 30
minutes and was then allowed to reach room temperature overnight. After 18 hours, the reaction
was concentrated in vacuo. The resulting oil was dissolved in 50 mL EtOAc and washed with
saturated NaHCO3 (3x25 mL). The Aqueous layer was then back extracted with EtOAc (2x20
mL). The combined organic layers were then dried with MgSO4 and concentrated in vacuo. The
resulting oil was purified via flash column chromatography (silica gel, 100% Et2O) to afford
0.2007 g (68% yield) of compound 3-13 as a clear foaming oil.
1

H NMR (300 MHz, Chloroform-d) δ 7.29 – 7.15 (m, 5H), 6.82 (d, J = 5.7 Hz, 1H), 5.82 – 5.62

(m, 1H), 5.42 (dd, J = 9.1, 3.8 Hz, 1H), 5.10 – 5.00 (m, 2H), 4.69 (d, J = 5.7 Hz, 1H), 4.30 (dd, J
= 7.4, 5.6 Hz, 1H), 3.96 – 3.79 (m, 2H), 3.24 (s, J = 2.3 Hz, 3H), 3.20 – 3.14 (m, 1H), 3.12 –
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3.02 (m, 1H), 2.87 (s, J = 11.4 Hz, 3H), 1.95 (s, J = 6.3 Hz, 3H), 1.50 – 1.38 (s, 9H), 1.17 – 1.11
(d, 3H), 0.81 (d, J = 6.4 Hz, 3H). Full characterization of compound 3-13 was not obtained as
this pathway was deemed unsuitable for future use.

[Compound 3-14] In a flame dried round bottom flask 0.3186 g (0.78 mmol) compound 3-12
was subjected to a benzene (30 mL) azeotropic distillation to remove any trace water. To this
flask was added 0.1975 g (0.75 mmol) triphenylphosphine, followed by 2.8 mL THF. The flask
was stirred at -30 °C before addition of 0.1900 g (0.93 mmol) compound 3-6 dissolved in an
additional 2.8 mL THF, followed by dropwise addition of 0.37 mL (0.82 mmol) of a 40 wt %
solution of Diethyl azodicarboxylate in toluene. The temperature was maintained at -30 °C for 30
minutes and was then allowed to reach room temperature overnight. After 18 hours, the reaction
was concentrated in vacuo. The resulting oil was dissolved in 50 mL EtOAc and washed with
saturated NaHCO3 (3x25 mL). The Aqueous layer was then back extracted with EtOAc (2x20
mL). The combined organic layers were then dried with MgSO4 and concentrated in vacuo. The
resulting oil was purified via flash column chromatography (silica gel, 50% Hexane: 10%
EtOAc: 40% Et2O) to afford 0.4097 g (88% yield) of compound 3-14 as a clear foaming oil.
1

H NMR (500 MHz, Chloroform-d) δ 7.29 – 7.20 (m, 6H), 6.87 (t, J = 5.9 Hz, 1H), 5.78 – 5.69

(m, 1H), 5.45 (dd, J = 8.2, 4.3 Hz, 1H), 5.18 (dd, J = 13.4, 6.7 Hz, 1H), 5.05 (dq, J = 14.0, 1.8
Hz, 2H), 4.77 (d, J = 5.4 Hz, 1H), 4.27 (t, J = 6.5 Hz, 1H), 3.92 (p, J = 6.2 Hz, 1H), 3.88 – 3.80
(m, 1H), 3.65 (s, 3H), 3.38 – 3.31 (m, 1H), 3.25 (s, 2H), 3.12 (dt, J = 14.3, 7.1 Hz, 1H), 2.91 (s,
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2H), 1.44 (d, J = 17.3 Hz, 9H), 1.15 (t, J = 7.1 Hz, 3H), 0.99 (d, J = 6.2 Hz, 3H); 13C NMR (126
MHz, cdcl3) δ 172.64, 172.06, 170.91, 159.87, 159.50, 138.70, 136.37, 132.35, 132.13, 131.09,
130.82, 118.76, 82.93, 79.08, 78.43, 72.83, 65.17, 61.47, 59.46, 55.27, 44.35, 40.30, 35.70,
30.92, 30.77, 30.76, 23.66, 19.50, 17.60. Full characterization of compound 3-14 was not
pursued as this synthetic route is still in development.
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Chapter Five: Conclusions and Future
Directions
5.1 Conclusions

Figure 5.1 – β-Elimination of the Bottom Bridge Analog
The effort to improve efficacy and potency of our simplified analogs is continuing with
the development of a convergent synthesis of analogs that contain an intact central building
block, or “bottom bridge” of the macrocycle. In this case, another pair of β-elimination reactions
continue to interfere with our progress. These β-elimination reactions involve the protons
highlighted in red in Figure 5.1. One destabilizes the functionalized bottom bridge, and the other
complicates the coupling of the N-methylamine within our central building block to the
carboxylic acid of left-hand portion of the macrocycle. While the exchange of the acetyl
protecting group to a methyl carbamate within the central building block improved yields and
slowed the β-elimination reaction, it is still problematic. The challenges with the formation of the
N-methyl amide have yet to be completely resolved, although progress is currently being made
by Dr. Yu Zhu in our group. The current hypothesis as to the challenges with the coupling
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reaction are highlighted in Figure 5.2. We propose that the challenge is related to problems
associated with coupling a NAcyl amino acid that were previously highlighted in Figure 2.5.

Figure 5.2 – Plausible Oxazolone Formation
To be more specific, it is possible, regardless of the size of the R group, that the
intramolecular nucleophilic trapping by the acyl amine of the activated ester necessary for the
desired coupling is faster than the bimolecular coupling. Following the displacement of the
leaving group for the activated ester, deprotonation of the proton involved in the β-elimination
results in an aromatic intermediate that rapidly undergoes the elimination of the TBS-alcohol.
While the ring opening of the oxazolone may be reversible, the β-elimination reaction is not. It
possible the opening of the oxazolone ring could lead to coupled product or be lost upon aqueous
work up. Efforts to solve this problem will be discussed in Section 5.2, though our experience
from the first-generation synthesis of WU-07047 suggests that at the very least the the βelimination at the core of the bottom bridge will continue to complicate the synthesis until the
macrocycle is assembled.
Despite this decomposition pathway, we chose to push forward in an attempt to
determine if the efficacy and potency would be improved through the installation of the bottom
bridge. We knew moving forward that this particular reaction sequence would not be scalable in
the future, but we hoped that positive result on the biological front would provide a foundation
for the synthetic efforts necessary to overcome the problems we have encountered. However,
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while trace amounts of material have been isolated from the coupling to the left-hand portion, the
amount of material generated have not been in sufficient yield to determine if the ring closing
metathesis strategy will be successful moving forward. The decision was made to carry trace
amounts of crude product forward to the ring closing metathesis (in order to reduce the risk of βelimination) but these efforts were inconclusive. Following purification after the metathesis
reaction, it was evident that polymeric product had been generated. We hypothesize that the
refluxing conditions necessary for the ring closing metathesis may increase the rate of the
problematic β-elimination. However, we need to be cautious drawing conclusions regarding the
metathesis reaction since the substrate for the reaction has not been characterized with respect to
purity.
The combined problems encountered with this route suggest that we should be devising
alternative strategies for the synthesis of more the functionalized analogs. What follows is a brief
discussion of future more functionalized analogs, and possible options aimed at avoiding the
issues discussed above.

5.2 Future Directions
Looking forward, if we intend to use the convergent approach outlined in Figure 4.1 to
synthesize more complex analogs, we must first address the challenges of coupling the central
building block to the left-hand piece. There is literature evidence of the success of a
macrolactamization of the NMe-amine of threonine (of our central building block) to the βhydroxyleucine (of our left-hand piece), although no yield is reported for this reaction.1 With the
knowledge that this coupling can be successful, there are two possible protecting group strategies
that may remedy the issue that we have observed to date. It may be plausible to find a suitable
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protecting group for the hydroxyl group in our left-hand portion that will avoid the β-elimination,
although we chose the TBDMS ether in an effort to do just that (Figure 5.3). If this approach
continues to be unsuccessful, we could alter the protecting group on the neighboring amine of the
left-hand piece to that of a carbamate group. We have already observed that a change from an
acyl group to a carbamate protecting group on an amine of an amino acid can reduce or eliminate
oxazolone formation in subsequent coupling reactions. There is evidence from Dr. Yu Zhu in our
group that such an approach can be successful. However, here we will emphasize the protecting
group strategy involving the hydroxy group of the left-hand piece. Solving the problem in this
manner will result in a shorter synthesis overall, eliminating the need to juggle protection groups
in the steps after the desired coupling reaction. Remember that the length of the synthesis may be
incredibly important because of the potential loss of material due to the β-elimination within the
bottom bridge during each subsequent reaction (Figure 4.2).

Figure 5.3 – Protection Strategies that Reduce the β-Elimination
There are two possible approaches when choosing a protecting group for the left-hand
piece. We can either find a protecting group that would result in the oxygen being an unstable
leaving group, or a protecting group large enough to prevent any base from accessing the proton
(highlighted red) responsible for the β-elimination. A few such options to consider would be a
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TIPS, trityl, or benzyl protecting group. In each case, the hope is that the protecting group would
be more stable than the TBS group. This is based upon the evidence of the β-elimination in both
the TBS protected left-hand piece, the left-hand piece with the unprotected hydroxyl group
(Figure 4.4-5) and the plausible oxazolone formation mechanism highlighted in Figure 5.2.

Figure 5.4 – Ring Closing Macrolactamization
This protecting group strategy will be necessary for any analog synthesized based on the
current convergent approach (Figure 5.4). Once the problem of the coupling reaction has been
resolved (there is precedence that indicates it is a solvable problem), we will need to turn our
attention to formation of the macrocycle. For this transformation, it may be necessary to avoid
the elevated temperatures typically associated with the ring closing metathesis reaction. These
harsher conditions may trigger the unwanted β-elimination reactions. One approach that would
avoid these harsh conditions would use a ring closing macrolactamization (highlighted red) to
complete the synthesis of macrocycle. Once the macrocycle has been generated, the βelimination within the bottom bridge should no longer be possible. We can then add the βhydroxy leucine tail in a similar manner as the second-generation synthesis.
If the methods that discussed above that attempt to reduce the β-elimination are not
successful, it is possible to synthesize analogs that will avoid the β-elimination in its entirety
(Figure 5.5).
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Figure 5.5 – Analogs that Avoid the β-Elimination
There are several approaches we have considered to avoid the β-elimination within our
central building block, two of which are actively being pursued in our lab. In the first analog
shown above (left, Figure 4.5), the carbonyl of the threonine of our central building block has
been reduced (highlighted red). This change would make the molecule more stable by
significantly reducing the leaving group ability of the portion of the molecule eliminated in the
unwanted side-reaction.

Scheme 5.1 – Threonine Reduction
The synthesis of this analog can in principle be accomplished by reduction of the
carboxylic acid in the original demethylated amino acid, conversion of the resulting hydroxy
group to a leaving group, and an SN2 type displacement of the leaving group by the secondary
alcohol of the threonine (Scheme 5.1).
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It is also possible to prevent the problematic β-elimination entirely through removal of
the problematic acidic proton via methylation (highlighted red) of the α-carbon of the right-hand
threonine (right, Figure 5.5). Amino acids of this nature have been synthesized.2 While these
options are plausible synthetically, the strategies may not be tolerated from the standpoint of
biological activity.
In addition, one could consider the use of a ring closing macrolactonization (highlighted
red) to complete the synthesis of our macrocycle (right, Figure 5.5). While this will require an
alternative coupling approach to assemble the acyclic molecule, by ring closing at the threonine
dimer, we would entirely avoid the chance of the β-elimination prior to forming the macrocycle
while still retaining the bottom bridge found in the natural products.

Figure 5.6 – Top Bridge Carbamate Analog
One final approach to consider is the use of a carbamate within the top bridge (Figure
5.6). The use of a carbamate in place of the amide found in the natural product should help avoid
oxazolone formation under standard coupling conditions. The installation of this the top bridge
with a carbamate will allow us to use the same building block approach to piece together the
linear molecule prior to the use of a ring closing metathesis to tie together the macrocycle. If this
method is unsuccessful, one could envision assembling the linear molecule in a stepwise fashion
(Scheme 5.2)
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Scheme 5.2: Carbamate Coupling Strategy
Efforts are currently underway in our lab if assembly of this molecule in a linear fashion
will avoid carbamate formation. Evidence found by Dr. Yu Zhu in our lab indicates that the
coupling between the NMe-OMe-Thr of the central building block, to the Boc protected βhydroxy leucine of the left hand piece is possible.

Figure 5.7 – Bioorthogonal Handle Analog
As we work to improve the potency and efficacy of our simplified analogs, it is becoming
clear we need to devise a rapid way to screen molecules for activity prior to the use of expensive
and time-consuming whole cell assays that are currently used. To this end, we are interested
installing a biorthogonal handle (R) such as an alkyne or an aryl bromide (Figure 5.7). This will
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serve two purposes, first, both groups have been used to place molecules onto microelectrode
arrays to monitor for binding to biological targets.3 Second, this synthetic addition will also
provide our medical school collaborators a handle for labeling the analogs in connection with
future biological assays. Both handles can be used to add several probes to previously
synthesized analogs. In Figure 5.7, I have suggested a site (highlighted red) where this handle
could potentially be installed. This site was chosen because the inclusion of larger groups at this
position in the natural product have been tolerated.4 For example, as discussed in Section 1.3, the
substitution of a phenyl group for the methyl group found in the natural product has been
tolerated with no significant loss in activity. The installation of an amino acid with a
bioorthoganal handle can be accomplished through standard coupling reactions.
All this work is currently underway in the Moeller group. These efforts seek to improve
potency and efficacy towards that found in the natural products, the development of methods for
the rapid screening of newly synthesized analogs, and the scaling of the synthesis for building
YM- and FR-analogs. These analogs will prove invaluable for probing the G protein signaling
pathways, as well as providing potential lead compounds for the development of therapeutics in
the future.
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Appendix: Spectral Data
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